Aryl sulfonamide compounds and their use in treating medical conditions
Aryl sulfonamide compounds are developed to enhance ABC transporter function, addressing the need for treatments for ABC transporter-related disorders by increasing protein expression and improving disease symptoms.
Patent Information
- Application Number
- PCT/US2024/029818
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
There is a need for small molecule compounds that can positively modulate ABC transporter function to treat diseases associated with ABC transporter dysfunction, such as cystic fibrosis, progressive familial intrahepatic cholestasis, and Alzheimer’s disease, where current treatments are inadequate.
Development of aryl sulfonamide compounds that can enhance ABC transporter function by increasing the expression of proteins like ABCB11, ABCB4, and ABCA4, administered as part of a pharmaceutical composition to treat disorders associated with ABC transporter dysfunction.
The aryl sulfonamide compounds effectively modulate ABC transporter function, potentially treating ABC transporter-related disorders by enhancing protein expression and improving disease symptoms.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000003_0002 
Figure IMGF000006_0001
Abstract
Description
ARYL SULFONAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICALCONDITIONSCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to United States Provisional Patent Application serial number 63 / 467,477 filed May 18, 2023, the contents of which are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION
[0002] The invention provides aryl sulfonamide compounds, pharmaceutical compositions, and their use in treating medical conditions.BACKGROUND
[0003] ATP-binding cassette (ABC) transporters are a large, phylogenetically conserved gene family with broad physiological and pathological relevance. [1,2] They are expressed throughout the body and transport a diverse range of substrates across lipid membranes. ABC transporters are transmembrane, ATP-binding proteins that use the energy released during ATP hydrolysis to move substrates from one side of a lipid membrane to the other. [2,3]
[0004] At least 21 ABC transporters underly rare monogenic disorders with even more implicated in the predisposition to and symptomology of common and complex diseases. Such broad (patho)physiological relevance places this class of proteins at the intersection of disease causation and therapeutic potential, underlining them as promising targets for drug discovery. Based on a handful of characterized disorders, including cystic fibrosis (CF), progressive familial intrahepatic cholestasis 2 (PFIC2), and Stargardt disease (STGD), there is a mechanistic commonality to pathogenic ABC transporter missense mutations, principally their impact on protein folding leading to endoplasmic reticulum (ER) degradation (trafficking defects), or protein function, leading to decreased substrate transport (transport defects). Importantly, small molecule compounds may enable treatment of disease symptoms not directly caused by mutations in ABC transporter genes.
[0005] There is a need for small molecule compounds that can positively modulate ABC transporter function and therefore be used for the treatment of diseases in which such enhancement is predicted to be of therapeutic value, either in modifying disease or in treating disease symptomology. For example, there is a need for modulators that can address mutations in ABCB11, ABCB4, ABCC6, ABCA4, ABCD1, ABCA1 and ABCA7 for the treatment of PFIC2, PFIC3, PXE / GACI, STGD, X-ALD and Alzheimer’s disease, respectively.
[0006] Accordingly, the need exists for new therapeutic methods and compounds for treating ABC transporter dysfunction. The present invention addresses the foregoing needs and provides other related advantages.SUMMARY
[0007] The invention provides aryl sulfonamide compounds, pharmaceutical compositions, and their use in treating medical conditions. In particular, one aspect of the invention provides a collection of aryl sulfonamide compounds, such as a compound represented by Formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of aryl sulfonamide compounds are described in the detailed description. The compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
[0008] Another aspect of the invention provides a collection of aryl sulfonamide compounds represented by Formula 1-1 :or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of aryl sulfonamide compounds are described in the detailed description. The compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
[0009] Another aspect of the invention provides a method of treating a disorder associated with ABC transporter dysfunction. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to treat the disorder, as further described in the detailed description.
[0010] Another aspect of the invention provides a method increasing the expression of a protein selected from ABCB11, ABCB11 E297G, ABCC6, ABCB4, ABCA4 P1380L, and ABCD2 in a subject. The method comprises administering to a subject in need thereof an effective amount of a compound described herein, such as a compound of Formula I, to thereby increase expression of said protein, as further described in the detailed description.DETAILED DESCRIPTION
[0011] The invention provides aryl sulfonamide compounds, pharmaceutical compositions, and their use in treating medical conditions. The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992); “Handbook of experimental immunology” (D.M. Weir & C.C. Blackwell, eds.); “Current protocols in molecular biology” (F.M. Ausubel etal., eds., 1987, and periodic updates); and “Current protocols in immunology” (J.E. Coligan etal., eds., 1991), each of which is herein incorporated by reference in its entirety.
[0012] Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls.Definitions
[0013] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “-O-alkyl” etc. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0014] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1 -6 aliphatic carbon atoms. In certain embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In certain embodiments, “cycloaliphatic” refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0015] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the termincludes any permissible ring fusion, such as o / 7 / w-fused or spirocyclic. As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In certain embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In certain embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:
[0016] Exemplary bridged bicyclics include:
[0017] The term “lower alkyl” refers to a C1.4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
[0018] The term “lower haloalkyl” refers to a C1-4straight or branched alkyl group that is substituted with one or more halogen atoms.
[0019] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2 / f-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).
[0020] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.
[0021] As used herein, the term “bivalent Ci-8 (or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
[0022] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n- wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0023] The term “-(Co alkylene)-“ refers to a bond. Accordingly, the term “-(Co-3 alkylene)-” encompasses a bond (i.e., Co) and a -(C1.3 alkylene)- group.
[0024] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0025] The term “halogen” means F, Cl, Br, or I.
[0026] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl group when it has two groups attached to it (e.g., “phenylene” is a trivalent phenyl group when it has three groups attached to it (e.g . The term “arylene” refers to a bivalentaryl group.
[0027] The terms “heteroaryl” and “heteroar-, ” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 > electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4J / -quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
[0028] The term “heteroarylene” refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it. For example, “heteroarylene” is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it.
[0029] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro- 2 / / pyrrol yl), NH (as in pyrrolidinyl), or+NR (as in A substituted pyrrolidinyl).
[0030] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3 / 7 indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl” refers to a heterocyclyl substituted by one or more oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it. The term “oxo-heterocyclylene” refers to a multivalent oxo-heterocyclyl group having the appropriate number of open valences to account for groups attached to it.
[0031] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0032] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structuremay be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0033] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from halogen; -(CEEjcwR0; -(CH2)o 4OR0; -0(CH2)o-4R°, -0-(CH2)o- 4C(O)OR°; -(CH2)O-4CH(OR°)2; -(CH2)O 4SR0; -(CEEjo ^Ph, which may be substituted with R°; -(CH2)o-40(CH2)o-iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o-40(CH2)o-i-pyridyl which may be substituted with R°; -NO2; -CN; - N3; -(CH2)O4N(RO)2; -(CH2)O4N(R°)C(O)R°; -N(R°)C(S)R°; -(CH2)O- ^N(RO)C(O)NR°2; -N(RO)C(S)NR°2; -(CH2)0^N(RO)C(O)OR°; -N(R°)N(R°)C(O)R°; -N(RO)N(R°)C(O)NRO2; -N(R°)N(R°)C(O)OR°; -(CH2)o4C(O)R°; -C(S)R°; -(CH2)(MC(0)0R°; -(CH2)O4C(O)SRO;-(CH2)O 4C(O)OSiR°3; -(CH2)O4OC(O)R°; -OC(0)(CH2)O-ISR-, SC(S)SR°; -(CH2)O4SC(O)RO; -(CH2)O 4C(O)NRO2; -C(S)NRO2; -C(S)SR°; -SC(S)SR°, -(CH2)O ^OC(O)NR°2;-C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)o 4SSR0; -(CH2)o-4S(O)2R°; -(CH2)O 4S(O)2ORO; -(CH2)O- ^OS(O)2R°; -S(0)2NRO2; -S(O)(NR°)R°; - S(O)2N=C(NRO2)2; -(CH2)O4S(O)RO; -N(RO)S(O)2NRO2; -N(RO)S(O)2R°; -N(OR°)R°; - C(NH)NR°2; -P(O)2RO; -P(O)R°2; -OP(O)R°2; -OP(O)(OR°)2; SiR°3; -(Ci^ straight or branched alkylene)O-N(R°)2; or -(C1-4straight or branched alkylene)C(O)O-N(R°)2.
[0034] Each R° is independently hydrogen, C1-6aliphatic, -CH2Ph, -0(CH2)o iPh, -CEl2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted by a divalent substituent on a saturated carbon atom of R° selected from =0 and =S; or each R° is optionally substituted with a monovalent substituentindependently selected from halogen, -(CH2)o-2R*, -(haloR*), -(CH2)o2OH, -(CH2)o-2OR*, - (CH2)o2CH(OR*)2; -O(haloR’), -CN, -N3, -(CH2)o-2C(0)R*, -(CH2)o-2C(0)OH, -(CH2)o-2C(O)OR*, -(CH2)O -2SR*, -(CH2)O 2SH, -(CH2)O 2NH2, -(CH2)o 2NHR*, -(CH2)0 2NR*2, -NO2, -SiR*3, -OSiR*3, -C(O)SR* — (Ci 4 straight or branched alkylene)C(O)OR*, or -SSR*.
[0035] Each R* is independently selected from Ci^ aliphatic, — CH2Ph, — 0(CH2)o iPh, or a 5— 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens; or wherein an optional substituent on a saturated carbon is a divalent substituent independently selected from =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =N0R*, -O(C(R*2))23O-, or- S(C(R*2))2-3S-, or a divalent substituent bound to vicinal substitutable carbons of an “optionally substituted” group is -O(CR*2)23O-, wherein each independent occurrence of R* is selected from hydrogen, C1-6aliphatic or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0036] When R* is C1-6aliphatic, R* is optionally substituted with halogen, - R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is independently selected from C1-4aliphatic, -CH2Ph, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens.
[0037] An optional substituent on a substitutable nitrogen is independently -R:, -NR^2, - C(O)Rf, -C(O)ORf, -C(O)C(O)Rt, -C(O)CH2C(O)Rt, -S(O)2R+, -S(O)2NRf2, -C(S)NRt2, - C(NH)NR’:2, or -N(R^)S(O)2Rt; wherein each R:is independently hydrogen, C1-6aliphatic, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R \ taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when R:is C1-6aliphatic, R:is optionally substituted with halogen, -R*, -(haloR*), -OH, -OR*, - O(haloR’), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* isindependently selected from C1-4aliphatic, -CH2Ph, -0(CH2) 0-1 Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens.
[0038] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
[0039] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, international J. of Pharmaceutics (1986) 33 201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book(Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference.
[0040] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+( C1-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[0041] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. The invention includes compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
[0042] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.
[0043] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present invention can have the S orR configuration as defined by the IUP AC 1974 Recommendations. Further, to the extent a compound described herein may exist as an atropisomer (e.g., substituted biaryls), all forms of such atropisomer are considered part of this invention.
[0044] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
[0045] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.
[0046] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and Ci-Ce alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3- methyl-1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3-methyl-l-pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l- butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
[0047] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group.
[0048] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.
[0049] The term “hydroxyalkyl” refers to an alkyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH2C(H)(OH)CH2CH2OH, and the like.
[0050] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
[0051] The terms “alkoxyl” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, / cvV-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like.
[0052] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane substituted with an oxo group is cyclopentanone.
[0053] The symbol “ ” indicates a point of attachment.
[0054] When any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.
[0055] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitablesolvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.
[0056] As used herein, the terms “subject” and “patient” are used interchangeable and refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans.
[0057] The term “IC50” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target.
[0058] The term “EC50” is art recognized and refers to the concentration of a compound that is required to achieve a response that is 50% of the maximum target effect relative to the baseline.
[0059] The term “Emax” is art recognized and refers to the concentration of a compound that is require to achieve maximal target effect.
[0060] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory or preventative result). An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
[0061] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
[0062] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA
[1975] ,
[0063] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non- pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
[0064] In addition, when a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts. Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
[0065] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
[0066] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.I. Aryl sulfonamide Compounds
[0067] One aspect of the invention provides aryl sulfonamide compounds. The compounds may be used in the pharmaceutical compositions and therapeutic methods described herein. Exemplary compounds are described in the following sections, along with exemplary procedures for making the compounds.
[0068] Accordingly, one aspect of the invention provides a compound represented byFormula I:wherein:R1is -L1-SO2-R6, -SO2N(R9)-R7, or -S(NH)(O)-R6;R2represents independently for each occurrence hydrogen, hydroxyl, C1-3alkyl, halo, C1-4alkoxyl, C1.3 haloalkyl, C1-3hydroxyalkyl, or optionally substituted cyclopropyl;R3and R4are independently hydrogen or C1-3alkyl;R3represents independently for each occurrence halo, cyano, C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, -CON(R10)2, or C1-6haloalkoxyl;R6is C1-4alkyl, C3-5cycloalkyl, phenyl, -(C0-2 alkylene)-(3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl, heterocycle, and heteroaryl are substituted with m instances of R8;R7is hydrogen, C1-4alkyl, C3.5 cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8;R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl;R9is hydrogen or C1-3alkyl;R10represents independently for each occurrence hydrogen, C1-4alkyl, or cyclopropyl;L1is -N(R9)- or a bond;A* is an 8-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;B1is phenylene or a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen; m is 0, 1, or 2; n is 0, 1, 2, or 3; o is 1, 2, or 3; and p is 0, 1 or 2
[0069] The definitions of variables in Formula I above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
[0070] In certain embodiments, the compound is a compound of Formula I.
[0071] As defined generally above, A* is an 8-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen. In certain embodiments, A* is an 8-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, A* is a 9-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing two heteroatoms, wherein the heteroatoms are nitrogen atoms. In certain embodiments, A* is an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, A* is azaindazolene or azaindolene. In certain embodiments, A* is selected from those disclosed in Table 1, below.
[0072] As defined generally above, R1is -V-SCh-R6, -SO2N(R9)-R7’, or -S(NH)(O)-R6. In certain embodiments, R1is -L1-SO2-R6. In certain embodiments, R1is -NHSO2-R6. In certain embodiments, R1is -SO2-R6. In certain embodiments, R1is -SO2N(R9)-R7. In certain embodiments, R1is -SO2NH-R7. In certain embodiments, R1is -S(NH)(O)-R6. In certain embodiments, R1is selected from those disclosed in Table 1, below.
[0073] As defined generally above, R2represents independently for each occurrence hydrogen, hydroxyl, C1-3alkyl, halo, Ci-4 alkoxyl, C1-3haloalkyl, C1.3 hydroxyalkyl, or optionally substituted cyclopropyl. In certain embodiments, R2is hydrogen. In certain embodiments, R2is hydroxyl. In certain embodiments, R2represents independently for each occurrence C1-3alkyl. In certain embodiments, R2represents independently for each occurrence halo. In certain embodiments, R2represents independently for each occurrence Ci-4alkoxyl. In certain embodiments, R2represents independently for each occurrence C1-3haloalkyl. In certain embodiments, R2represents independently for each occurrence C1-3hydroxyalkyl. In certain embodiments, R2is optionally substituted cyclopropyl. In certain embodiments, R2is cyclopropyl. In certain embodiments, R2represents independently for each occurrence C1.3 alkyl, halo, C1-3haloalkyl, or cyclopropyl. In certain embodiments, R2represents independently for each occurrence methyl or optionally substituted cyclopropyl. In certain embodiments, R2represents independently for each occurrence methyl or cyclopropyl. In certain embodiments, R2represents independently for each occurrence methyl or 1 -methylcyclopropyl.
[0074] In certain embodiments, R2is hydrogen, hydroxyl, C1-3alkyl, halo, C1.3 haloalkyl, or cyclopropyl. In certain embodiments, R2is C1.3 alkyl. In certain embodiments, R2is halo. In certain embodiments, R2is Ci-4 alkoxyl. In certain embodiments, R2is C1-3haloalkyl. In certain embodiments, R2is C1-3hydroxyalkyl. In certain embodiments, R2is C1-3alkyl, halo, C1-3haloalkyl, or cyclopropyl. In certain embodiments, R2is methyl or cyclopropyl. In certain embodiments, R2is selected from those disclosed in Table 1, below.
[0075] As defined generally above, R3and R4are independently hydrogen or C1-3alkyl. In certain embodiments, R3and R4are independently C1-3alkyl. In certain embodiments, R3and R4are hydrogen. In certain embodiments, R3and R4are C1-3alkyl. In certain embodiments, R3is hydrogen. In certain embodiments, R3is C1-3alkyl. In certain embodiments, R3is methyl. In certain embodiments, R3is selected from those disclosed in Table 1, below.
[0076] In certain embodiments, R4is hydrogen. In certain embodiments, R4is C1-3alkyl. In certain embodiments, R4is methyl. In certain embodiments, R3and R4are independently selected from those disclosed in Table 1, below.
[0077] As defined generally above, R5represents independently for each occurrence halo, cyano, C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, -CON(R10)2, or C1-6haloalkoxyl. In certain embodiments, R5represents independently for each occurrence C1-6alkyl, C1-6haloalkyl,hydroxyl, C1-6alkoxyl, -CON(R10)2, or C1-6haloalkoxyl. In certain embodiments, R5represents independently for each occurrence halo, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, -CON(R10)2, or C1-6haloalkoxyl. In certain embodiments, R3represents independently for each occurrence halo, C1-6alkyl, hydroxyl, C1-6alkoxyl, -CON(R10)2, or C1-6haloalkoxyl. In certain embodiments, R3represents independently for each occurrence halo, C1-6alkyl, C1-6haloalkyl, Cue alkoxyl, - CONH(R10), or C1-6haloalkoxyl. In certain embodiments, R3represents independently for each occurrence halo, C1-6alkyl, Cue haloalkyl, hydroxyl, or -CONH(R10), C1-6haloalkoxyl. In certain embodiments, R5represents independently for each occurrence halo, C1-6alkyl, C1-6haloalkyl, hydroxyl, or C1-6alkoxyl.
[0078] In certain embodiments, R5represents independently for each occurrence halo. In certain embodiments, R3represents independently for each occurrence C1-6alkyl. In certain embodiments, R5represents independently for each occurrence C1-6haloalkyl. In certain embodiments, R5represents independently for each occurrence C1-6alkoxyl. In certain embodiments, R3represents independently for each occurrence -CONH(R10). In certain embodiments, R5represents independently for each occurrence -CON(R10)2. In certain embodiments, R5represents independently for each occurrence C1-6haloalkoxyl.
[0079] In certain embodiments, R5is halo. In certain embodiments, R3is F. In certain embodiments, R5is cyano. In certain embodiments, R5is C1-6alkyl. In certain embodiments, R5is methyl. In certain embodiments, R5is C1-6haloalkyl. In certain embodiments, R3is -CF3. In certain embodiments, R3is hydroxyl. In certain embodiments, R5is C1-6alkoxyl. In certain embodiments, R5is -OMe. In certain embodiments, R5is -CONH(R8). In certain embodiments, R5is C1-6haloalkoxyl. In certain embodiments, R3is selected from those disclosed in Table 1, below.
[0080] As defined generally above, R6is C1-4alkyl, C3-5cycloalkyl, phenyl, -(C0-2 alkylene)- (3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl, heterocycle, and heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certainembodiments, R6is C1-4alkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C1-4alkyl, C3-5cycloalkyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C1-4alkyl, C3-5cycloalkyl, or phenyl, wherein the cycloalkyl is substituted with m instances of R8.
[0081] In certain embodiments, R6is C1-4alkyl. In certain embodiments, R6is Z-butyl. In certain embodiments, R6is C3-5cycloalkyl, substituted with m instances of R8. In certain embodiments, R6is cyclopropyl, substituted with m instances of R8. In certain embodiments, R6is phenyl. In certain embodiments, R6is -(C0-2 alkylene)-(3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), substituted with m instances of R8. In certain embodiments, R6is -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl is substituted with m instances of R8. In certain embodiments, R6is selected from those disclosed in Table 1, below.
[0082] As defined generally above, R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, or -(Co- 2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8.
[0083] In certain embodiments, R7is C1.4 alkyl, C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)- (5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R7is hydrogen, C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R7is hydrogen, C1-4alkyl, phenyl, or -(C0-2 alkylene)- (5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl is substituted with m instances of R8. In certain embodiments, R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, or -(Co-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen,oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, wherein the cycloalkyl is substituted with m instances of R8.
[0084] In certain embodiments, R7is hydrogen. In certain embodiments, R7is C1-4alkyl. In certain embodiments, R7is / -butyl. In certain embodiments, R7is C3-5cycloalkyl, substituted with m instances of R8. In certain embodiments, R7is cyclopropyl, substituted with m instances ofR8. In certain embodiments, R7is phenyl. In certain embodiments, R7is -(Co-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl is substituted with m instances of R8. In certain embodiments, R7is selected from those disclosed in Table 1, below.
[0085] As defined generally above, R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence halo, C1-3haloalkyl, hydroxyl, C1.4 alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, Ci-3 haloalkyl, hydroxyl, C1.4 alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, halo, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1.4 alkyl, halo, C1-3haloalkyl, C1-4alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, cyano, or cyclopropyl. As defined generally above, R8represents independently for each occurrence C1.4 alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, or cyano.
[0086] In certain embodiments, R8represents independently for each occurrence C1-4alkyl. In certain embodiments, R8represents independently for each occurrence halo. In certain embodiments, R8represents independently for each occurrence C1-3haloalkyl. In certain embodiments, R8represents independently for each occurrence C1-4alkoxy.
[0087] In certain embodiments, R8is C1-4alkyl. In certain embodiments, R8is methyl. In certain embodiments, R8is halo. In certain embodiments, R8is C1.3 haloalkyl. In certain embodiments, R8is C1-4alkoxy. In certain embodiments, R8is cyano. In certain embodiments, R8is Ci-4 alkyl or C1-3haloalkyl. In certain embodiments, R8is selected from those disclosed in Table 1, below.
[0088] As defined generally above, R9is hydrogen or C1-3alkyl. In certain embodiments, R9is hydrogen. In certain embodiments, R9is C1-3alkyl. In certain embodiments, R9is selected from those disclosed in Table 1, below.
[0089] As defined generally above, R10represents independently for each occurrence hydrogen, C1-4alkyl, or cyclopropyl. In certain embodiments, R10represents independently for each occurrence hydrogen. In certain embodiments, R10represents independently for each occurrence C1-4alkyl. In certain embodiments, R10represents independently for each occurrence cyclopropyl. In certain embodiments, R10represents independently for each occurrence hydrogen or C1-4alkyl. In certain embodiments, R10represents independently for each occurrence hydrogen or cyclopropyl. In certain embodiments, R10is selected from those disclosed in Table 1, below.
[0090] As defined generally above, L1is -N(R9)- or a bond. In certain embodiments, L1is - N(R9)-. In certain embodiments, L1is a bond. In certain embodiments, L1is selected from those disclosed in Table 1, below.
[0091] As defined generally above, B1is phenylene or a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen. In certain embodiments, B1is phenylene. In certain embodiments, B1is a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen. In certain embodiments, B1is pyridinylene, pyrimidylene, pyridazinylene, pyrazinylene, or phenylene. In certain embodiments, B1is pyridinylene. In certain embodiments, B1is pyrimidylene. In certain embodiments, B1is pyridazinylene. In certain embodiments, B1is pyrazinylene. In certain embodiments, B1is phenylene. In certain embodiments, B1is selected from those disclosed in Table 1, below.
[0092] As defined generally above, m is 0, 1, or 2. In certain embodiments, m is 1 or 2. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0093] As defined generally above, n is 0, 1, 2, or 3. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is 1 or 2. In certain embodiments, n is 0. In certain embodiments, n is 1.In certain embodiments, n is 2. In certain embodiments, n is 1 or 2. In certain embodiments, n is 3. In certain embodiments, n is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0094] As defined generally above, o is 1, 2, or 3. In certain embodiments, o is 2 or 3. In certain embodiments, o is 1 or 2. In certain embodiments, o is 0. In certain embodiments, o is 1. In certain embodiments, o is 2. In certain embodiments, o is 1 or 3. In certain embodiments, o is 3. In certain embodiments, o is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0095] As defined generally above, p is 0, 1, or 2. In certain embodiments, p is 1 or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0096] Another aspect of the invention provides a compound represented by Formula 1-1 :or a pharmaceutically acceptable salt thereof; wherein:R1is -lASCh-R6, -SO2N(R9)-R7’, or -S(NH)(O)-R6;R2represents independently for each occurrence hydrogen, hydroxyl, C1-3alkyl, halo, C1-4alkoxyl, C1-3haloalkyl, C1-3hydroxyalkyl, or optionally substituted cyclopropyl;R3and R4are independently hydrogen or C1-3alkyl;R?represents independently for each occurrence halo, cyano, C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, or C1-6haloalkoxyl;R6is C1-4alkyl, C3-5cycloalkyl, phenyl, -(C0-2 alkylene)-(3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl, heterocycle, and heteroaryl are substituted with m instances of R8;R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8;R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl;R9is hydrogen or C1-3alkyl;L1is -N(R9)- or a bond;A1is a 5-6 membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur;B1is phenylene or a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen; m is 0, 1, or 2; n is 0, 1, 2, or 3; and o is 1, 2, or 3.
[0097] The definitions of variables in Formula 1-1 above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
[0098] In certain embodiments, the compound is a compound of Formula 1-1.
[0099] As defined generally above, R1is -L'-SCh-R6, -SC>2N(R9)-R7, or -S(NH)(O)-R6. In certain embodiments, R1is -iJ-SCh-R6. In certain embodiments, R1is -NHSO2-R6. In certain embodiments, R1is -SO2-R6. In certain embodiments, R1is -SO2N(R9)-R7. In certain embodiments, R1is -SO2NH-R7. In certain embodiments, R1is -S(NH)(O)-R6. In certain embodiments, R1is selected from those disclosed in Table 1, below.
[0100] As defined generally above, R2represents independently for each occurrence hydrogen, hydroxyl, C1-3alkyl, halo, Ci-4 alkoxyl, C1-3haloalkyl, C1.3 hydroxyalkyl, or optionallysubstituted cyclopropyl. In certain embodiments, R2is hydrogen. In certain embodiments, R2is hydroxyl. In certain embodiments, R2represents independently for each occurrence C1-3alkyl. In certain embodiments, R2represents independently for each occurrence halo. In certain embodiments, R2represents independently for each occurrence Ci-4 alkoxyl. In certain embodiments, R2represents independently for each occurrence C1-3haloalkyl. In certain embodiments, R2represents independently for each occurrence C1-3hydroxyalkyl. In certain embodiments, R2is optionally substituted cyclopropyl. In certain embodiments, R2is cyclopropyl. In certain embodiments, R2represents independently for each occurrence C1.3 alkyl, halo, C1-3haloalkyl, or cyclopropyl. In certain embodiments, R2represents independently for each occurrence methyl or optionally substituted cyclopropyl. In certain embodiments, R2represents independently for each occurrence methyl or cyclopropyl. In certain embodiments, R2represents independently for each occurrence methyl or 1-methylcyclopropyl.
[0101] In certain embodiments, R2is hydrogen, hydroxyl, C1-3alkyl, halo, C1-3haloalkyl, or cyclopropyl. In certain embodiments, R2is C1.3 alkyl. In certain embodiments, R2is halo. In certain embodiments, R2is Ci-4 alkoxyl. In certain embodiments, R2is C1-3haloalkyl. In certain embodiments, R2is C1-3hydroxy alkyl. In certain embodiments, R2is C1-3alkyl, halo, C1-3haloalkyl, or cyclopropyl. In certain embodiments, R2is methyl or cyclopropyl. In certain embodiments, R2is selected from those disclosed in Table 1, below.
[0102] As defined generally above, R3and R4are independently hydrogen or C1-3alkyl. In certain embodiments, R3and R4are independently C1.3 alkyl. In certain embodiments, R3and R4are hydrogen. In certain embodiments, R3and R4are C1-3alkyl.
[0103] In certain embodiments, R3is hydrogen. In certain embodiments, R3is C1-3alkyl. In certain embodiments, R3is methyl. In certain embodiments, R4is hydrogen. In certain embodiments, R4is C1-3alkyl. In certain embodiments, R4is methyl. In certain embodiments, R3and R4are independently selected from those disclosed in Table 1, below.
[0104] As defined generally above, R5represents independently for each occurrence halo, cyano, C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, or C 1-6 haloalkoxyl. In certain embodiments, R?represents independently for each occurrence C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, or C1-6haloalkoxyl. In certain embodiments, R5represents independently for each occurrence halo, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, or C1-6haloalkoxyl. In certain embodiments, R5represents independently for each occurrence halo, C1-6alkyl, hydroxyl, C1-6alkoxyl, or C1-6haloalkoxyl. In certain embodiments, R represents independently for each occurrence halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, or C1-6haloalkoxyl. In certain embodiments, R? represents independently for each occurrence halo, C1-6alkyl, C1-6haloalkyl, hydroxyl, or C1-6haloalkoxyl. In certain embodiments, R represents independently for each occurrence halo, C1-6alkyl, C1-6haloalkyl, hydroxyl, or C1-6alkoxyl.
[0105] In certain embodiments, R5represents independently for each occurrence halo. In certain embodiments, R5represents independently for each occurrence C1-6alkyl. In certain embodiments, R5represents independently for each occurrence C1-6haloalkyl. In certain embodiments, R?represents independently for each occurrence C1-6alkoxyl. In certain embodiments, R5represents independently for each occurrence C1-6haloalkoxyl.
[0106] In certain embodiments, R5is halo. In certain embodiments, R5is F. In certain embodiments, R5is cyano. In certain embodiments, R3is C1-6alkyl. In certain embodiments, R5is methyl. In certain embodiments, R5is C1-6haloalkyl. In certain embodiments, R5is -CF3. In certain embodiments, R3is hydroxyl. In certain embodiments, R5is C1-6alkoxyl. In certain embodiments, R5is -OMe. In certain embodiments, R5is C1-6haloalkoxyl. In certain embodiments, R5is selected from those disclosed in Table 1, below.
[0107] As defined generally above, R6is C1-4alkyl, C3-5cycloalkyl, phenyl, -(C0-2 alkylene)- (3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl, heterocycle, and heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C1-4alkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C1-4alkyl, C3-5cycloalkyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R6is C1-4alkyl, C3-5cycloalkyl, or phenyl, wherein the cycloalkyl is substituted with m instances of R8.
[0108] In certain embodiments, R6is C1-4alkyl. In certain embodiments, R6is / -butyl. In certain embodiments, R6is C3-5cycloalkyl, substituted with m instances of R8. In certain embodiments, R6is cyclopropyl, substituted with m instances of R8. In certain embodiments, R6is phenyl. In certain embodiments, R6is -(C0-2 alkylene)-(3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), substituted with m instances of R8. In certain embodiments, R6is -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl is substituted with m instances of R8. In certain embodiments, R6is selected from those disclosed in Table 1, below.
[0109] As defined generally above, R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, or -(Co- 2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8.
[0110] In certain embodiments, R7is C1.4 alkyl, C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)- (5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R7is hydrogen, C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R7is hydrogen, C1-4alkyl, phenyl, or -(C0-2 alkylene)- (5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl is substituted with m instances of R8. In certain embodiments, R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, or -(Co-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8. In certain embodiments, R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, wherein the cycloalkyl is substituted with m instances of R8.
[0111] In certain embodiments, R7is hydrogen. In certain embodiments, R7is C1-4alkyl. In certain embodiments, R7is / -butyl. In certain embodiments, R7is C3-5cycloalkyl, substituted with m instances of R8. In certain embodiments, R7is cyclopropyl, substituted with m instances of R8. In certain embodiments, R7is phenyl. In certain embodiments, R7is -(Co-2 alkylene)-(5-6membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the heteroaryl is substituted with m instances of R8. In certain embodiments, R7is selected from those disclosed in Table 1, below.
[0112] As defined generally above, R8represents independently for each occurrence Ci-4 alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence halo, C1-3haloalkyl, hydroxyl, C1.4 alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, Ci-3 haloalkyl, hydroxyl, C1.4 alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, halo, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1.4 alkyl, halo, C1-3haloalkyl, C1-4alkoxy, cyano, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, cyano, or cyclopropyl. As defined generally above, R8represents independently for each occurrence C1.4 alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, or cyclopropyl. In certain embodiments, R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, or cyano.
[0113] In certain embodiments, R8represents independently for each occurrence C1-4alkyl. In certain embodiments, R8represents independently for each occurrence halo. In certain embodiments, R8represents independently for each occurrence C1-3haloalkyl. In certain embodiments, R8represents independently for each occurrence C1.4 alkoxy.
[0114] In certain embodiments, R8is C1-4alkyl. In certain embodiments, R8is methyl. In certain embodiments, R8is halo. In certain embodiments, R8is C1.3 haloalkyl. In certain embodiments, R8is C1-4alkoxy. In certain embodiments, R8is cyano. In certain embodiments, R8is C1-4alkyl or C1-3haloalkyl. In certain embodiments, R8is selected from those disclosed in Table 1, below.
[0115] As defined generally above, R9is hydrogen or C1-3alkyl. In certain embodiments, R9is hydrogen. In certain embodiments, R9is C1.3 alkyl. In certain embodiments, R9is selected from those disclosed in Table 1, below.
[0116] As defined generally above, L1is -N(R9)- or a bond. In certain embodiments, L1is - N(R9)-. In certain embodiments, L1is a bond. In certain embodiments, L1is selected from those disclosed in Table 1, below.
[0117] As defined generally above, A1is a 5-6 membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In certain embodiments, A1is a 5 membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In certain embodiments, A1is a 5 membered aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In certain embodiments, A1is a 5 membered partially unsaturated ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In certain embodiments, A1is a 5 membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from nitrogen. In certain embodiments, A1is a 6 membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In certain embodiments, A1is selected from those disclosed in Table 1, below.
[0118] As defined generally above, B1is phenylene or a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen. In certain embodiments, B1is phenylene. In certain embodiments, B1is a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen. In certain embodiments, B1is pyridinylene, pyrimidylene, pyridazinylene, pyrazinylene, or phenylene. In certain embodiments, B1is pyridinylene. In certain embodiments, B1is pyrimidylene. In certain embodiments, B1is pyridazinylene. In certain embodiments, B1is pyrazinylene. In certain embodiments, B1is phenylene. In certain embodiments, B1is selected from those disclosed in Table 1, below.
[0119] As defined generally above, m is 0, 1, or 2. In certain embodiments, m is 1 or 2. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0120] As defined generally above, n is 0, 1, 2, or 3. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is 1 or 2. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 1 or 2. In certain embodiments, n is 3. In certain embodiments, n is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0121] As defined generally above, o is 1, 2, or 3. In certain embodiments, o is 2 or 3. In certain embodiments, o is 1 or 2. In certain embodiments, o is 0. In certain embodiments, o is 1. In certain embodiments, o is 2. In certain embodiments, o is 1 or 3. In certain embodiments, o is 3. In certain embodiments, o is selected from the corresponding value in the groups depicted in the compounds in Table 1 below.
[0122] In certain embodiments, the compound of Formula 1-1 is further defined by Formula I- A or a pharmaceutically acceptable salt thereof
[0123] In certain embodiments, the compound is a compound of Formula I-A.
[0124] In certain embodiments, compound has the following formula or a pharmaceutically acceptable salt thereof
[0125] In certain embodiments, the compound of Formula 1-1 is further defined by Formula I- B, I-C, I-D, I-E, or I-F, or a pharmaceutically acceptable salt thereof
[0126] In certain embodiments, the compound is a compound of Formula I-B, I-C, I-D, I-E, or I-F.
[0127] In certain embodiments, the compound of Formula 1-1 is further defined by Formula I-G or a pharmaceutically acceptable salt thereof:
[0128] In certain embodiments, the compound is a compound of Formula I-G.
[0129] In certain embodiments, the compound of Formula 1-1 is further defined by Formula I-H, I-I, I- J, I-K, I-L, I-M, or I-N or a pharmaceutically acceptable salt thereof:
[0130] In certain embodiments, the compound is a compound of Formula I-H, I-I, I-J, I-K, I- L, I-M, or I-N.
[0131] In certain embodiments, the compound of Formula 1-1 is further defined by Formula I- O, I-P, I-Q, or I-R, or a pharmaceutically acceptable salt thereof:
[0132] In certain embodiments, the compound is a compound of Formula I-O, I-P, I-Q, or I-R.Exemplary Speci fic Compounds
[0133] In certain embodiments, the compound is a compound in Table 1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1.TABLE 1. Exemplary Compounds
[0134] In certain embodiments, the present invention provides a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle for use as a medicament.
[0135] In certain embodiments, the present invention provides a compound set forth in TableI, above, or a pharmaceutically acceptable salt thereof. In certain embodiments, the present invention provides a compound set forth in Table 1, above. In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound set forth in Table 1 above, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, excipient, or diluent.II. Therapeutic Applications
[0136] In certain embodiments, the present invention provides a method of treating a disorder in which enhanced ABC transporter function is of clinical benefit. For instance, in certain embodiments, a disorder is one in which ABC transporter dysfunction is etiological for disease. In certain embodiments, correction of one or more underlying mutations associated with ABC transporter dysfunction is rationalized. In certain embodiments, methods of the present invention provide enhancement of one or more non-mutated forms of an ABC transporter.
[0137] In certain embodiments, the invention provides a method of treating a disorder in which enhanced ABC transporter function is of clinical benefit, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to treat the disorder in which enhanced ABC transporter function is of clinical benefit. In certain embodiments, the particular compound of Formula l is a compound defined by one of the embodiments described in Section I, above.
[0138] In certain embodiments, the invention provides a method of treating a disorder associated with ABC transporter dysfunction, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to treat the disorder associated with ABC transporter dysfunction. In certain embodiments, the particular compound of Formula I is a compound defined by one of the embodiments described in Section I, above.
[0139] In certain embodiments, the invention provides a method of treating a disorder described herein, comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to treat the disorder.
[0140] In certain embodiments, the present invention provides a method of alleviating one or more symptoms of a disorder associated with ABC transporter dysfunction, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to treat the disorder associated with ABC transporter dysfunction. In certain embodiments, the particular compound of Formula l is a compound defined by one of the embodiments described in Section I, above.
[0141] In certain embodiments, the disorder associated with ABC transporter dysfunction is characterized by dysfunction in a transporter selected from one or more of ABCA1, ABCA2, ABCA3, ABCA4, ABCA5, ABCA7, ABCA12, ABCB2, ABCB3, ABCB4, ABCB6, ABCB7, ABCB10, ABCB11, ABCC1, ABCC2, ABCC4, ABCC5, ABCC6, ABCC7, ABCC8, ABCC9, ABCC12, ABCD1, ABCD2, ABCD3, ABCD4 , ABCG5, ABCG8, ABCG1, and ABCG4.
[0142] In certain embodiments, the present invention provides methods of treating a disorder selected from Tangier disease, Surfactant metabolism dysfunction pulmonary 3, autosomal recessive Ichthyosis congenital 4A (ARCI), Bare lymphocyte syndrome type I, Bare lymphocytesyndrome type I due to TAP2 deficiency, Dyschromatosis universalis hereditaria 3, X-linked sideroblastic anemia with ataxia, Dubin-Johnson Syndrome, Cystic fibrosis (CF), Familial Hyperinsulinemic Hypoglycemia 1, Intellectual disability Myopathy Syndrome, Congenital bile acid synthesis defect 5, Methylmalonic aciduria and homocystinuria cblJ type, Sitostrolemia, Stargardt disease, PFIC3, PFIC2, Pseudoxanthoma Elasticum, X-linked adrenoleukodystrophy (ALD), Cholestasis, Hyperbilirubinemia, Intrahepatic cholestasis of pregnancy, Biliary atresia, Alagille syndrome, primary biliary cholangitis, primary sclerosing cholangitis, NAFLD / NASH, Alzheimer's disease, Huntington's disease, Multiple sclerosis, Parkinson’s disease, Hirschsprung disease, Zellweger syndrome, Type 2 diabetes, Obesity, Type 1 diabetes, Atherosclerosis, Dyslipidemia, Generalized arterial calcification of infancy, Calciphylaxis, Autosomal recessive cone-rod dystrophy, Gout, PFIC1, Myo5B deficiency cholestasis, PFIC4, and Low phospholipid associated cholelithiasis.
[0143] In certain embodiments, the disorder associated with ABC transporter dysfunction is cystic fibrosis (CF). Accordingly, in certain embodiments, the present invention provides a method of treating cystic fibrosis, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I. In some such embodiments, the method further comprises administering one or more additional therapeutic agents, described further below and herein.
[0144] In certain embodiments, the disorder associated with ABC transporter dysfunction is cholestasis. Accordingly, in certain embodiments, the present invention provides a method of treating cholestasis, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I. One of skill in the medical arts will recognize that there are various forms of cholestasis, all of which are contemplated herein for treatment with methods and compounds of the present invention. In certain embodiments, the cholestasis is intrahepatic. In certain embodiments, the cholestasis is extrahepatic. In certain embodiments, the cholestasis is any of those described above and herein.
[0145] Another aspect of the invention provides a method increasing the expression of a protein selected from ABCB11, ABCB11 E297G, ABCC6, ABCB4, ABCA4 P1380L, and ABCD2 in a subject, wherein the method comprises administering to a subject in need thereof aneffective amount of a compound described herein, such as a compound of Formula I, to thereby increase expression of said protein.
[0146] In certain embodiments, the protein is ABCB 11. In certain embodiments, the protein is ABCB 11 E297G. In certain embodiments, the protein is ABCC6. In certain embodiments, the protein is ABCB4. In certain embodiments, the protein is ABCA4 P1380L. In certain embodiments, the protein is ABCD2.Subjects
[0147] In certain embodiments, the subject is a human. In certain embodiments, the subject is an adult human. In certain embodiments, the subject is a pediatric human.Medical Uses
[0148] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, or other compounds in Section I) in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disorder described herein, such as a disorder associated with ABC transporter dysfunction. Exemplary such disorders are described above and herein.
[0149] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, or other compounds in Section I) for treating a medical disorder, such as disorder associated with ABC transporter dysfunction. Exemplary such disorders are described above and herein.III. Combination Therapy
[0150] Another aspect of the invention provides for combination therapy. Compounds described herein (such as a compound of Formula I, or other compounds in Section I) or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat medical disorders, such as an autoimmune disorder, cancer, etc..
[0151] In certain embodiments, the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and coadministering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In certain embodiments, the method includesco-administering one additional therapeutic agent. In certain embodiments, the method includes co-administering two additional therapeutic agents. In certain embodiments, the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically.
[0152] One or more other therapeutic agent may be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent and a compound or composition of the invention may be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, or 24 hours from one another. In certain embodiments, one or more other therapeutic agent and a compound or composition of the invention are administered as a multiple dosage regimen more than 24 hours apart.
[0153] In certain embodiments, the present invention provides a method of treating cystic fibrosis (CF) comprising administering a compound of the present invention with one or more additional therapeutic agents. In certain embodiments, the one or more additional therapeutic agents are selected from a mucolytic agent, a bronchodialator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a cystic fibrosis transmembrane conductance (CFTR) modulator, a nutritional agent, or any agent known to treat CF.
[0154] In certain embodiments, the one or more additional therapeutic agents is an S- nitrosoglutathione reductase (GSNOR) inhibitor. In certain embodiments, the GSNOR inhibitor is selected from a GSNOR inhibitor disclosed in W02010 / 019903, U.S. Pat. No. 8,470,857, U.S. Pat. No.8,642,628, W02010 / 019910, U.S. Pat. No.8,586,624, WO2011 / 100433, U.S. Pat. No.US 8,481,590, W02012 / 048181, WO2012 / 083165, W02012 / 083171, or WO 2012 / 170371.
[0155] In certain embodiments, the one or more additional therapeutic agents is an ileal bile transport (IB AT) inhibitor. In certain embodiments, the IBAT inhibitor is selected from an IBAT inhibitor disclosed in AU2011326873, US2020 / 0330545, WO2012 / 064266, W02020 / 167964, or Front. Pharmacol. 2018; 9: 931 (Al-Dury et al., published online August 21, 2018). ExemplaryIBAT inhibitors include, but are not limited to odevixibat, elobixivat, maralixibat, linerixibat, GSK2330672, SHP626 (volixibat), A4250, etc.Additional Considerations
[0156] The doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician. In certain embodiments, the compound described herein (such as a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disorder. In other embodiments, the compound described herein (such as a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder. In certain embodiments, the compound described herein (such as a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.
[0157] In certain embodiments, the compound described herein (such as a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) may act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and / or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.
[0158] Another aspect of this invention is a kit comprising a therapeutically effective amount of the compound described herein (such as a compound of Formula I, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above.IV. Pharmaceutical Compositions and Dosing Considerations
[0159] As indicated above, the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and / or diluents. The pharmaceutical compositions may be specially formulated for administration insolid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. In certain embodiments, the invention provides a pharmaceutical composition comprising a compound described herein (such as a compound of Formula I, or other compounds in Section I) and a pharmaceutically acceptable carrier.
[0160] The phrase “therapeutically effective amount” as used herein means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit / risk ratio applicable to any medical treatment.
[0161] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0162] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0163] Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0164] Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
[0165] In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and poly anhydrides; and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention.
[0166] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[0167] Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
[0168] In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fdlers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0169] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0170] The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may besterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
[0171] Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, com, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0172] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0173] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0174] Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
[0175] Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[0176] Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
[0177] The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0178] Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0179] Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
[0180] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
[0181] Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectablesolutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0182] Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0183] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
[0184] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0185] Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
[0186] When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[0187] The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
[0188] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
[0189] The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
[0190] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intraci sternally and topically, as by powders, ointments or drops, including buccally and sublingually.
[0191] Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and / or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
[0192] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[0193] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
[0194] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
[0195] In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the compounds are administered at about 0.01 mg / kg to about 200 mg / kg, more preferably at about 0.1 mg / kg to about 100 mg / kg, even more preferably at about 0.5 mg / kg to about 50 mg / kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone.
[0196] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
[0197] The invention further provides a unit dosage form (such as a tablet or capsule) comprising a compound described herein in a therapeutically effective amount for the treatment of a medical disorder described herein.EXAMPLES
[0198] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and is not intended to limit the invention.Synthetic Methods
[0199] Methods for preparing compounds described herein are illustrated in the following synthetic Scheme. The Scheme is given for the purpose of illustrating the invention, and not intended to limit the scope or spirit of the invention. Starting materials shown in the Scheme can be obtained from commercial sources or can be prepared based on procedures described in the literature.
[0200] In the Schemes, it is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated (for example, use of protecting groups or alternative reactions). Protecting group chemistry and strategy is well known in the art, for example, as described in detail in “Protecting Groups in Organic Synthesis”, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, the entire contents of which are hereby incorporated by reference. The modular synthetic route illustrated in Scheme 1 can also be readily modified by one of skill in the art to provide additional compounds by conducting functional group transformations on the intermediate and final compounds. Such functional group transformations are well known in the art, as described in, for example, “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992).
[0201] The abbreviation “TFA” refers to trifluoroacetic acid. The abbreviation “FA” refers to formic acid.Preparative HPLC Methods:
[0202] Preparative HPLC Method 1 :Instrument: Gilson-GX281Mobile Phase: H2O(0.1% TFA) (solvent A) and CH3CN (solvent B), Gradient: using the elution gradient 15%-95% (solvent B) over 25 minutes.Flow rate: 25 ml / min;Column: Nanomicro-Uni Sil 5-120 C18 ,5um, 30*150 mmWavelength: UV 220 nm and 254 nm)Column temperature: 25 °C;MS ionization: ESI.
[0203] Preparative HPLC Method 2:Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(10 mmol / L NH4HC03+0.05%NH3H20), Mobile Phase B: ACN;Gradient: 10% B to 35% B in 7min;Flow rate: 60 mL / min;Column: XBridge Shield RP18 OBD Column, 30*150 mm, 7 pm;Wave Length: UV 254 nm and 222 nmMS ionization: ESI.
[0204] Preparative HPLC Method 3 :Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(10 mmol / L NH4HC03+0.05%NH3H20), Mobile Phase B: ACN;Gradient: 23% B to 43% B in 7min;Flow rate: 60 mL / min;Column: XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm;MS ionization: ESI.Wave Length: UV 254nm and 220nm.
[0205] Preparative HPLC Method 4:Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(0.1% FA), Mobile Phase B: ACN;Gradient: 30% B to 40% B in 7 min;Flow rate: 60 mL / min;Column: Xselect CSH C18 OBD Column 30*150 mm 6 pm;Wave Length: UV 254 nm and 220 nm;MS ionization: ESI.
[0206] Preparative HPLC Method 5 :Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(10 mmol / L NH4HC03+0.05% NH3H2O), Mobile Phase B: ACN;Gradient: 14% B to 39% B in 7 min;Flow rate: 60 mL / min;Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 pm;Wave Length: 220nmMS ionization: ESI.
[0207] Preparative HPLC Method 6:Instrument: Shimadzu LCMS-2020Mobile Phase A: Water (10 mmol / L NH4HCO3) +0.05%NH3.H20, Mobile Phase B: ACN;Gradient: 23% B to 50% B in 7min;Flow rate: 60 mL / min;Column: XBridge Prep OBD C18 Column, 30*150 mm, 5pm;Wave Length: 254 nm and 220 nmMS ionization: ESI.
[0208] Preparative HPLC Method 7 :Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(10 mmol / L NH4HC03+0.05% NH3H2O), Mobile Phase B: ACN;Gradient: 10% B to 37% B in 7 min;Flow rate: 60 mL / min;Column: XBridge Prep OBD C18 Column, 30*150 mm, 5pm;Wave Length: 254 nM / 220 nmMS ionization: ESI.
[0209] Preparative HPLC Method 8 :Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(10 mmol / L NH4HC03+0.05% NH3H2O), Mobile Phase B: ACN;Gradient: 9% B to 28% B in 7 min;Flow rate: 60 mL / min;Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 pm;Wave Length: 254 nM / 220 nmMS ionization: ESI.
[0210] Preparative HPLC Method 9:Instrument: Shimadzu LCMS-2020Mobile Phase A: Water(10 mmol / L NH4HC03+0.05% NH3H2O), Mobile Phase B: MeOH;Gradient: 12% B to 35% B in 10 min;Flow rate: 25 mL / min;Column: XB ridge Prep OBD C18 Column, 19*250 mm, 5 pm;Wave Length: 254nM / 220nmMS ionization: ESI.Analytical LCMS Methods:
[0211] Analytical LC / MS Analysis Method A :(0-70%-positive-negative)ESI+ / - ion mode 100-1000 DaWavelength: UV 220 nm / 254 nmColumn: Shim-pack C18, 50*4.6 mm, 5 pm or Welch Xtimate C18, 250*4.6 mm, 5 pm or YMC-Triart Cl 8, 50*4.6 mm, 5 pmTemperature: 40°CGradient:
[0212] Analytical LC / MS Analysis Method B:(positive-negative 3min-l)ESI+Z- ion mode 100-1000 DaWavelength: UV 220 nm / 254 nmColumn: YMC-Triart Cl 8, 50*4. 6mm, 5 pm or Shim-pack Cl 8, 50*4.6 mm, 5 pmTemperature: 40°CGradient:
[0213] Analytical LC / MS Analysis Method C:(0-50%-positive-3min)ESI+ / - ion mode 100-1000 DaWavelength: UV 220 nm / 254 nmColumn: YMC-Triart C18, 50*4.6 mm, 5 pm or Shim-Pack Scepter C18, 33*3.0 mm, 3 pmTemperature: 40°CGradient:
[0214] Analytical LC / MS Analysis Method D: (0-70%-positive-negative)ESI+Z- ion mode 100-1000 DaWavelength: UV 220 nm / 254 nmColumn: YMC-Triart Cl 8, 50><4.6mm, 5 pmTemperature: 40°CGradient:
[0215] Analytical LC / MS Analysis Method E:ESI+ / - ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Shim-pack Scepter C18-120, 33*3.0 mm, 3 pmTemperature: 30°CGradient:
[0216] Analytical LC / MS Analysis Method F:ESU7- ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Shim-pack Scepter C18, 33*3.0 mm, 3 pmTemperature: 30°CGradient:
[0217] Analytical LC / MS Analysis Method G:ESI+ / - ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Shim-pack Scepter C18, 33*3.0 mm, 3 pmTemperature: 30°CGradient:
[0218] Analytical LC / MS Analysis Method H:ESI+ / - ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Shim-pack Scepter C18-120, 33*3.0 mm, 3 pmTemperature: 30°CGradient:
[0219] Analytical LC / MS Analysis Method I:ESH7- ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Halo Cl 8, 30*3.0 mm, 2.0 pumTemperature: 40°CGradient:
[0220] Analytical LC / MS Analysis Method J:ESI+ / - ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Shim-pack Scepter C18-120, 33*3.0 mm, 3 pmTemperature: 30°CGradient:
[0221] Analytical LC / MS Analysis Method K:ESI+ / - ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Halo Cl 8, 30*3.0 mm, 2.0 pmTemperature: 40°CGradient:
[0222] Analytical LC / MS Analysis Method L:ESI+ / - ion mode 90-900Wavelength: UV 254 nm / ELSDColumn: Halo Cl 8, 30*3.0mm, 2.0 jamTemperature: 40°CGradient:Example 1 - Method A: Synthesis of Compound 1-16
[0223] Step 1 : To a solution of 2-bromo-6-chloro-3-methylpyridine (R-l, 3 g, 14.6 mmol, 1.0 eq.) and 6-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-((2-(trimethylsilyl) ethoxy)methyl)-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (R-2, prepared based on procedures in US2015 / 148342, 5.9 g, 14.6 mmol, 1.0 eq.) in dioxane / H2O (50 mL, v / v =5: 1) were added K2CO3 (6.04 g, 43.8 mmol, 3.0 eq.) and Pd(PPhi)4 (842 mg, 0.73 mmol, 0.05 eq.). The resulting mixture was stirred at 90 °C for 12 h under N2. After completion, the reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatographyon silica gel (eluted with EtOAc in PE 0 to 30%) to afford Int-1 (5.8 g, 14.4 mmol, 98%) as an oil. LCMS (ESI): m,z = 404 [M+H]+.
[0224] Step 2: To a solution of Int-1 (2.2 g, 5.46 mmol, 1.0 eq.) and 2-methylpropane-2- sulfonamide (748 mg, 5.46 mmol, 1.0 eq.) in dioxane (30 mL) were added CS2CO3 (5.33 g, 16.4 mmol, 3.0 eq.), BrettPhos Pd G3 (990 mg, 1.09 mmol, 0.2 eq.) and BrettPhos (880 mg, 1.64 mmol, 0.3 eq.). The resulting mixture was stirred at 110 °C for 16 h under N2. After completion, the reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluted with EtOAc in PE 0 to 55%) to afford Int-2 (1.0 g, 1.98 mmol, 36%) as an oil. LCMS (ESI): m / 'z = 505 [M+H]+.
[0225] Step 3: A solution of Int-2 (1.0 g, 1.98 mmol, 1.0 eq.) in HC1 (cone.) / THF (10 mL / 10 mL) was stirred at room temperature for 0.5 h. The mixture was concentrated under reduced pressure. The residue was dissolved in NH3.H2O (10 mL) and the resulting mixture was stirred at room temperature for 0.5 h whereupon, the mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (Method 1) to afford Compound 1-16 (450 mg, 61%) as a white solid.
[0226] The following compounds were made using Method A, from the appropriate sulfonamides: Compounds 1-2-5, 7-9, and 11-15.Example 2 - Synthesis of Compound 1-10
[0227] Step 1: To a solution of Int-1 (50 mg, 0.12 mmol, 1.0 eq.) and methanesulfonamide (12 mg, 0.12 mmol, 1.0 eq.) in dioxane (5 mL) were added CS2CO3 (78 mg, 0.24 mmol, 2.0 eq.), BrettPhos Pd G3 (990 mg, 24 pmol, 0.2 eq.) and BrettPhos (19 mg, 36 pmol, 0.3 eq ). Theresulting mixture was stirred at 1 10 °C for 16 h under N2. After completion, the reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluted with EtOAc in PE 0 to 55%) to afford Int-3 (26 mg, 56 pmol, 46%) as an oil. LCMS (ESI): m z = 463 [M+H]+.
[0228] Step 2: A solution of Int-3 (26 mg, 56 qmol, 1.0 eq.) in HC1 (con.) / THF (1 mL / 1 mL) was stirred at room temperature for 0.5 h. The mixture was then concentrated under reduced pressure the residue was dissolved in NH3.H2O (2 mL) and the resulting mixture was stirred at room temperature for 0.5 h. The reaction mixture was then concentrated under reduced pressure. The residue was purified by prep-HPLC (Method 1) to afford Compound 1-10 (10 mg, 53%) as a white solid.Example 3 - Method B: Synthesis of Compound 1-20
[0229] Step 1 : A mixture of 5-bromo-6-chloropyridin-2-amine (R-3, 3 g, 14.461 mmol, 1 equiv), cyclopropylboronic acid (2.48 g, 28.922 mmol, 2 equiv), Na2COs (3.07 g, 28.922 mmol, 2 equiv) and Pd(dppf)Ch (2.12 g, 2.892 mmol, 0.2 equiv) in THF (50 mL) and H2O (10 mL) was stirred for 16h at 80°C under N2 atmosphere. The mixture was allowed to cool down to RT. The resulting mixture was concentrated under reduced pressure. The residue was purified by silicagel column chromatography, eluted with PE / EA (3 / 1) to afford Int-4 (2 g, 82.02%) as a brown solid. LC-MS: M+H found: 169.05.
[0230] Step 2: A mixture of Int-4 (100 mg, 0.593 mmol, 1 equiv), R-4 (prepared based on procedures in WO 2018 / 188047) (381.01 mg, 0.889 mmol, 1.5 equiv), Pd(PPh3)4 (137.06 mg, 0.119 mmol, 0.2 equiv) and Na2COs (125.71 mg, 1.186 mmol, 2 equiv) in 1,4-dioxane (2 mL) and H2O (0.2 mL) was stirred for 4h at 100°C under N2 atmosphere. The mixture was allowed to cool down to RT. The residue was purified by silica gel column chromatography, eluted with DCM / MeOH (15:1) to afford Int-5 (250 mg, 97.02%) as a yellow oil. LC-MS: M+H found: 435.25.
[0231] Step 3: To a stirred solution of Int-5 (100 mg, 0.230 mmol, 1 equiv) in pyridine (1 mL) was added methanesulfonic anhydride (60.13 mg, 0.345 mmol, 1.5 equiv) at room temperature. The resulting reaction mixture was stirred at rt for Ih, then was acidified to pH 2 with HC1 (IM). The aqueous layer was extracted with EA (3x15 mL). The residue was purified by Prep-TLC (DCM / MeOH=15 / l) to afford Int-6 (lOOmg, 84.7%) as a white solid. LC- MS: M+H found: 513.05.
[0232] Step 4: To a stirred solution of Int-6 (100 mg, 0.195 mmol, 1 equiv) in MeOH (1 mL) was added CS2CO3 (317.81 mg, 0.975 mmol, 5 equiv) at rt. The resulting reaction mixture was stirred at 50°C for Ih, then was concentrated under reduced pressure to give the crude product, which was purified by Prep-HPLC (Method 2) to afford Compound 1-20 (37.6 mg, 53.56%) as a white solid. 'H NMR (400 MHz, DMSO-d6) 5 12.06 (s, IH), 10.59 - 10.16 (m, IH), 7.44 (s, IH), 7.39 (d, J = 8.5 Hz, IH), 7.29 (t, J = 2.7 Hz, IH), 6.85 (d, J = 8.5 Hz, IH), 6.42 (s, IH), 3.58 (s, 3H), 3.27 (s, 3H), 1.95 (t, J = 7.3 Hz, IH), 0.96 - 0.78 (m, 2H), 0.63 (dd, J = 5.3, 1.8 Hz, 2H).Example 4 - Method C: Synthesis of Compound 1-27
[0233] Step 1 : A mixture of Int-5 (100 mg, 0.230 mmol, 1 equiv) and 2-methylpropane-2- sulfinyl chloride (48.55 mg, 0.345 mmol, 1.5 equiv) in pyridine (2 mL) was stirred at rt under ambient atmosphere for 2 h. The reaction mixture was then concentrated under reduced pressure, and the crude residue was purified by Prep-TLC (DCM / MeOH=10 / l) to afford Int-7 (100 mg, 80.66%) as a white solid. LC-MS: M+H found: 539.00.
[0234] Step 2: A mixture of Int-7 (100 mg, 0.186 mmol, 1 equiv) and m-CPBA (32.03 mg, 0.186 mmol, 1 equiv) in DCM (2 mL) was stirred at rt for Ih. The reaction mixture was then concentrated under reduced pressure, and the residue was purified by Prep-TLC (DCM / MeOH=15 / l) to afford Int-8 as a white solid. LC-MS: M+H found: 555.15.
[0235] Step 3: A stirred solution of Int-8 (80 mg, 0.144 mmol, 1 equiv) in MeOH (1 mL) was treated with CS2CO3 (234.96 mg, 0.720 mmol, 5 equiv) at rt under N2 atmosphere. The reaction mixture was stirred at RT for 2 h, and then was concentrated under reduced pressure. The crude product was purified by reverse phase HPLC (Method 3) to afford Compound 1-27 (18.7 mg, 32.15%) as a white solid. ‘HNMR (400 MHz, DMSO-d6) 8 12.07 (s, IH), 10.12 (s, IH), 7.81 - 6.70 (m, 4H), 6.22 (d, J = 2.8 Hz, IH), 3.58 (s, 3H), 1.83 (s, IH), 1.29 (s, 9H), 0.82 (d, J = 8.2 Hz, 2H), 0.64 (dd, J = 5.3, 1.9 Hz, 2H).Example 5 - Method D: Synthesis of Compound 1-17
[0236] Step 1 : To a stirred solution of Int-5 (100 mg, 0.230 mmol, 1 equiv) and DMAP (2.81 mg, 0.023 mmol, 0.1 equiv) in Pyridine (1 mL) was added 1 -methylcyclopropane- 1 -sulfonyl chloride (53.37 mg, 0.345 mmol, 1.5 equiv) at room temperature. The resulting reaction mixture was stirred at 80°C for 4 h. The reaction mixture was then concentrated under reduced pressure, and the crude residue was purified by Prep-TLC (DCM / MeOH=15 / l) to afford Int-9 (100 mg, 78.62%) as a white solid. LC-MS: M+H found: 553.10.
[0237] Step 2: To a stirred solution of Int-9 (100 mg, 0.181 mmol, 1 equiv) in MeOH (1 mL) was added CS2CO3 (88.43 mg, 0.271 mmol, 1.5 equiv) at room temperature. The resulting reaction mixture was stirred at rt for 2 h, then was concentrated under reduced pressure. The crude residue was purified by reverse phase HPLC (Method 4) to afford Compound 1-17 (20.5 mg, 28.40%) as a pink solid. NMR (400 MHz, DMSO-d6) 8 12.07 (s, 1H), 10.35 (s, 1H), 7.50- 7.23 (m, 3H), 7.08 (d, J = 8.5 Hz, 1H), 6.25 (t, J = 2.4 Hz, 1H), 3.58 (s, 3H), 1.85 (tt, J = 8.9, 5.3 Hz, 1H), 1.41 (s, 3H), 1.24 (t, J = 3.4 Hz, 2H), 0.88 - 0.78 (m, 2H), 0.78 - 0.72 (m, 2H), 0.68- 0.59 (m, 2H).
[0238] The following compounds were made using Method D, from the appropriate sulfonylchloride: Compounds 1-19, 21-24, and 26.Example 6 - Method E: Synthesis of Compound 1-18
[0239] Step 1 : To a stirred solution of 6H-thieno[2,3-c]pyridin-7-one (R-5, 1 g, 6.615 mmol, 1 equiv) in DMF (12 mL) was added NBS (1412.77 mg, 7.938 mmol, 1.20 equiv) dropwise at rt, and the resulting reaction mixture was stirred at rt for 2 h. The reaction mixture was then diluted with water, then was extracted with EA (3 x 6mL). The combined organic layers were washed with brine (3xl0mL), and then dried over anhydrous NasSCU After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with DCM / MeOH (20 / 1) to afford Int-10 (780 mg, 51.25%) as a yellow solid. LC-MS: M+H found: 231.9.
[0240] Step 2: To a stirred solution of Int-10 (400 mg, 1.739 mmol, 1 equiv) and Mel (271.44 mg, 1.913 mmol, 1.1 equiv) in THF (6 mL) was added LiHMDS (581.82 mg, 3 All mmol, 2.00 equiv) in portions at rt, and the reaction mixture was stirred at rt under N2 atmosphere for 16 h. The reaction mixture was then diluted with water, and extracted with EA (3 x 6mL). The combined organic layers were washed with brine (3xl0mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified byPrep-TLC (DCM / MeOH = 20 / 1) to afford Int-11 (185 mg, 43.59%) as a yellow solid. LC-MS:M+H found: 243.9.
[0241] Step 3: To a stirred solution of Int-11 (160 mg, 0.655 mmol, 1 equiv) and bis(pinacolato)diboron (332.89 mg, 1.310 mmol, 2 equiv) in dioxane (2 mL) was added KO Ac (128.65 mg, 1.310 mmol, 2 equiv) and Pd(PPhs)4 (3.34 mg, 0.004 mmol, 0.1 equiv) in portions at rt, and the resulting reaction mixture was stirred at 80°C under N2 atmosphere. After 2 h, the resulting mixture was concentrated under reduced pressure. The residue was purified by Prep- TLC (PE / EA=2 / 1) to afford Int-12 (120 mg, 62.88%) as a yellow solid. LC-MS: M+H found: 292.0.
[0242] Step 4: To a stirred solution of Int-4 (300 mg, 1.779 mmol, 1 equiv) in pyridine (4 mL) was added 2-methylpropane-2-sulfmyl chloride (375.30 mg, 2.668 mmol, 1.5 equiv) in portions at rt, and the reaction mixture was stirred at rt under N2 atmosphere for 2 h. The reaction mixture was then diluted with water (3mL), and extracted with EA (3 x 6mL). The combined organic layers were washed with brine (3x1 OmL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM: MeOH = 20: 1) to afford Int-13 (100 mg, 19.46%) as a yellow solid. LC-MS: M+H found: 289.1.
[0243] Step 5: To a stirred solution of Int-13 (230 mg, 0.796 mmol, 1 equiv) and Int-12 (371.03 mg, 1.274 mmol, 1.6 equiv) in dioxane (3 mL) and H2O (0.6 mL) were added K2CO3 (220.14 mg, 1.592 mmol, 2 equiv) and Pd(dppf)C12.CH2C12 (64.88 mg, 0.080 mmol, 0.1 equiv) in portions at rt, and the resulting reaction mixture was stirred at 80°C under N2 atmosphere for 2 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM / MeOH=20 / l) to give the crude product. The crude product (120mg) was purified by Prep-HPLC (Method 5) to afford Compound 1-18 (70 mg, 36.49%) as a grey white solid. ‘H NMR (400 MHz, DMSO-d6) 5 10.23 (s, 1H), 8.04 (d, J = 5.3 Hz, 1H), 7.79 (s, 1H), 7.42 (d, J = 8.7 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.18 (d, J = 5.3 Hz, 1H), 3.62 (s, 3H), 1.79 (tt, J = 8.6, 5.1 Hz, 1H), 1.30 (s, 9H), 0.83 (h, J = 4.3 Hz, 2H), 0.65 (dt, J = 5.4, 2.9 Hz, 2H).Example 7 - Method F: Synthesis of Compound 1-25
[0244] Step 1 : A solution of Int-4 (500 mg, 2.965 mmol, 1 equiv) and cyclopropanesulfonyl chloride (2.08 g, 14.825 mmol, 5 equiv) in pyridine (5 mL) was stirred for 16 h at 50°C, whereupon the desired product could be detected by LCMS. The reaction mixture was allowed to cool down to RT, then was concentrated under reduced pressure. The resulting crude mixture was extracted with EA (3 x 8ml). The combined organic layers were washed with brine (2x10ml), and then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product Int-14 was used in the next step directly without further purification. LCMS: m / z =273 [M+H],
[0245] Step 2: A mixture of Int-14 (670 mg, 2.456 mmol, 1 equiv) and NaH (117.90 mg, 4.912 mmol, 2 equiv) in DMF (7 mL) was stirred for 1 h at RT. To the reaction mixture was then added Mel (383.53 mg, 2.702 mmol, 1.1 equiv) dropwise at RT. The resulting reaction mixture was stirred for an additional 1 h at RT, whereupon the desired product could be detected by LCMS. The reaction was then quenched with H2O at RT. The resulting crude reaction mixture was extracted with EA (3 x 10ml). The combined organic layers were washed with brine (2x15ml), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product Int-15 was used in the next step directly without further purification. LCMS: m / z =287 [M+H],
[0246] Step 3: To a stirred mixture of Int-15 (430 mg, 1 .499 mmol, 1 equiv) and R-4 (prepared based on procedures in WO 2018 / 188047) (963.35 mg, 2.248 mmol, 1.5 equiv) in THF (5 mL) and H2O (1 mL) were added Na2COa (317.85 mg, 2.998 mmol, 2 equiv) and XPhos Pd G3 (253.85 mg, 0.300 mmol, 0.2 equiv) in portions at RT under N2 atmosphere. The resulting mixture was stirred for 1 h at 50°C, whereupon the mixture was allowed to cool down to RT. The crude reaction mixture was then extracted with EA (3 x 8ml), and the combined organic layers were washed with brine (2x10ml), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE: EA (1 :1) to afford Int-16 (455 mg, 54.91%) as a light-brown solid. LCMS: m / z =553 [M+H],
[0247] Step 4: A mixture of Int-16 (300 mg, 0.543 mmol, 1 equiv) and CS2CO3 (884.32 mg, 2.715 mmol, 5 equiv) in MeOH (5 mL) was stirred for 16 h at RT. The resulting mixture was concentrated under reduced pressure, and the crude residue was purified by Prep-TLC (DCM:MeOEI=15:l) to afford crude product. The crude product was purified by Prep-HPLC (Method 6) to afford Compound 1-25 (83 mg, 38.33%) as a white solid. LCMS: m / z =399.25 [M+H], 'H NMR (400 MHz, DMSO-d6) 8 12.08 (s, 1H), 7.49 - 7.40 (m, 2H), 7.35 - 7.26 (m, 2H), 6.31 (t, J = 2.3 Hz, 1H), 3.59 (s, 3H), 3.30 (s, 3H), 2.86 (tt, J = 7.8, 5.0 Hz, 1H), 1.98 (td, J = 8.4, 4.3 Hz, 1H), 0.97 - 0.86 (m, 6H), 0.75 - 0.68 (m, 2H).Example 8 - Method G: Synthesis of Compound 1-28
[0248] Step 1: To a solution of R-6 (300 mg, 1.47 mmol, 1.0 eq.) and phenylmethanethiol (219 mg, 1.76 mmol, 1.2 eq.) in toluene (10 mL) were added DIEA (569 mg, 4.41 mmol, 3.0 eq.), Pd(OAc)2 (24 mg, 147 pmol, 0.1 eq.) and XantPhos (170 mg, 294 pmol, 0.2 eq.). The resulting reaction mixture was stirred at 90 °C for 4 h, whereupon the reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash column chromatography on silica gel (eluted with EtOAc in PE 0 to 50%) to afford Int-17 (293 mg, 1.18 mmol, 80%) as an oil. LCMS (ESI): m / z = 250 [M+H]1.
[0249] Step 2: To a solution of Int-17 (210 mg, 0.84 mmol, 1.0 eq.) in H2SO4 (con. 5 mL) was added NaClO (1 mL, 20 wt% in H2O) at 0 °C. The resulting reaction mixture was stirred at 0 °C for 1 h, whereupon the reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL x 3). The organic layers were combined and washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluted with EtOAc in PE 0 to 50%) to afford Int-18 (140 mg, 0.62 mmol, 74%) as a yellow oil. LCMS (ESI): m / z = 226 [M+H]L
[0250] Step 3: To a solution of t-BuNEE (45 mg, 0.62 mmol, 1.0 eq.) and TEA (188 mg, 1.86 mmol, 3.0 eq.) in DCM (5 mL) was added Int-18 (140 mg, 0.62 mmol, 1.0 eq.) at 0 °C. The resulting reaction mixture was allowed to warm to room temperature and stirred for 0.5 h, whereupon the reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL x 3). The organic layers were combined and washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluted with EtOAc in PE 0 to 50%) to afford Int-19 (126 mg, 0.48 mmol, 78%) as a yellow oil. LCMS (ESI): m / z = 263 [M+H]+.
[0251] Step 4: To a solution of Int-19 (126 mg, 0.48 mmol, 1.0 eq.) and R-2 (prepared based on procedures in US2015 / 148342)(194 mg, 0.48 mmol, 1.0 eq.) in dioxane / EEO (5 mL, v / v =5:1) were added Na2COs (153 mg, 1.44 mmol, 3.0 eq.) and Pd(dppf)Ch (34 mg, 48 pmol, 0.1 eq.).The resulting reaction mixture was stirred at 100 °C for 8 h, whereupon the reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (eluted with EtOAc in PE 0 to 50%) to afford Int-20 (180 mg, 0.36 mmol, 75%) as an oil. LCMS (ESI): m / z = 505 [M+H]+.
[0252] Step 5: A solution of Int-19 (180 mg, 0.36 mmol, 1.0 eq.) in HC1 (con.) / THF (1 mL / 1 mL) was stirred at room temperature for 0.5 h. The mixture was concentrated under reduced pressure. The residue was dissolved in NH3.H2O (1 mL) and the resulting mixture was stirred at room temperature for 0.5 h, whereupon the mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (Method 1) to afford Compound 1-28 (52.4 mg, 39%) as a white solid. LCMS (ESI): m / z = 375.3 [M+H]+.Example 9 - Method H: Synthesis of Compound 1-6
[0253] Step 1 : To a mixture of R-l (100 mg, 0.49 mmol, 1.0 eq.) and hexamethyldistannane (161 mg, 0.49 mmol, 1.0 eq.) in dioxane (2 mL) was added Pd(dppf)Ch (18 mg, 25 pmol, 0.05 eq.). The resulting reaction mixture was stirred at 100 °C for 48 h under N2, whereupon the reaction mixture was concentrated under reduced pressure to afford Int-21 (100 mg, quant.) as an oil, which was taken on to the next step without further purification. LCMS (ESI): m / z = 291 [M+H]+.
[0254] Step 2: To a solution of 5-bromo-7-methyl-l,7-naphthyridin-8(7H)-one (as prepared in J. Med. Chem. 2016, 59, 10, 4462-4475) (100 mg, 0.42 mmol, 1.0 eq.) and Int-21 (100 mg, crude) in dioxane (5 mL) were added Cui (16 mg, 84 pmol, 0.2 eq.) and CsF (255 mg, 1.68mmol, 4.0 eq.). The resulting reaction mixture was stirred at 100 °C for 2 h under N2, whereupon the reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash column chromatography on silica gel (eluted with MeOH in DCM 0 to 10%) to afford Int- 22 (25 mg, 88 pmol, 21%) as a light-yellow solid. LCMS (ESI): m / z = 286 [M+H]+.
[0255] Step 3: To a solution of Int-22 (25 mg, 88 pmol, 1.0 eq.) and 2-methylpropane-2- sulfonamide (14 mg, 106 pmol, 1.2 eq.) in dioxane (2 mL) were added CS2CO3 (86 mg, 264 pmol, 3.0 eq.), BrettPhos Pd G3 (16 mg, 18 pmol, 0.2 eq.) and BrettPhos (14 mg, 26 pmol, 0.3 eq.). The resulting reaction mixture was stirred at 100 °C for 1 h under N2, whereupon the reaction mixture was concentrated under reduced pressure. The crude reaction mixture was then poured into H2O (5 mL) and extracted with DCM (10 mL x 3). The organic layers were combined and washed with brine (5 mL), dried over anhydrous ISfeSCU and concentrated under reduced pressure. The residue was purified by prep-HPLC (Method 1) to afford Compound 1-6 (2.1 mg, 5 pmol, 1%) as a white solid. LCMS (ESI): m / z = 387.4 [M+H]+. 'H NMR (400 MHz, DMSO) 5 8.65 (br, 1H), 7.79-7.45 (m, 6H), 3.83 (s, 3H), 2.19 (s, 3H).Example 10 - Method I: Synthesis of Compound 1-1
[0256] Step 1 : To a solution of Int-11 (50 mg, 0.21 mmol, 1.0 eq.) and Int-21 (50 mg, crude) in dioxane (2 mL) were added Cui (8 mg, 41 pmol, 0.2 eq.) and CsF (128 mg, 0.84 mmol, 4.0 eq.). The resulting mixture was stirred at 100 °C for 2 h under N2. After completion, the reaction mixture was concentrated under reduced pressure. Then the reaction mixture was concentratedunder reduced pressure. The residue was purified by flash column chromatography on silica gel (eluted with MeOH in DCM 0 to 10%) to afford Int-23 (15 mg, 52 pmol, 25%) as a light-yellow solid. LCMS (ESI): m,z = 291 [M+H]+.
[0257] Step 2: To a solution of Int-23 (15 mg, 52 pmol, 1.0 eq.) and 2-methylpropane-2- sulfonamide (8 mg, 62 pmol, 1.2 eq.) in dioxane (2 mL) were added CS2CO3 (51 mg, 156 pmol, 3.0 eq.), BrettPhos Pd G3 (9 mg, 10 pmol, 0.2 eq.) and BrettPhos (8 mg, 16 gmol, 0.3 eq.). The resulting mixture was stirred at 100 °C for 1 hr under N2. After completion, the reaction mixture was concentrated under reduced pressure. Then the reaction mixture was poured into H2O (5 mL) and extracted with DCM (10 mL x 3). The organic layers were combined and washed with brine (5 mL), dried over anhydrous Na2SCU and concentrated under reduced pressure. The residue was purified by prep-HPLC (Method 1) to afford Compound 1-1 (1.5 mg, 4 pmol, 8%) as a white solid. LCMS (ESI): m / z = 392.1 [M+H]+. ’H NMR (400 MHz, MeOD) 5 7.94 (d, J = 5.2 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.62 (s, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.12 (d, J = 5.3 Hz, 1H), 3.73 (s, 3H), 2.21 (s, 3H), 1.39 (s, 9H).Example 11 - Method J: Synthesis of Compound 1-91
[0258] Step 1 : A mixture of R-l (500 mg, 2.422 mmol, 1 equiv) and (methyl sulfanyl) sodium (203.65 mg, 2.906 mmol, 1.2 equiv) in DMSO (5 mL) was stirred for 3h at RT. The resulting mixture was quenched with water (20 mL), extracted with EA (3 x 20 ml), and the combined organic layers were then washed with saturated brine (2x50 ml), and dried overanhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE / EA (10: 1)) to afford Int-24 (340 mg, 80.85%) as a yellow solid. LCMS (ESI): m 'z = 174 [M+H]+.
[0259] Step 2: A solution of Int-24 (330 mg, 1.900 mmol, 1 equiv) in DCM (3 mL) was treated with m-CPBA (2623.28 mg, 15.200 mmol, 8 equiv) in portions at RT. The resulting mixture was stirred for 3h at RT, whereupon the reaction was quenched by the addition of Na2SzO3 solution (20 ml) at RT. The resulting mixture was extracted with DCM (3 x 30 ml), and the combined organic layers were washed with saturated NaHCOa solution (2x30 ml), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (eluted with PE / EA (1 : 1)) to afford Int-25 (300 mg, 76.76%) as a yellow solid. LCMS (ESI): m'z = 206 [M+H]-.
[0260] Step 3: A mixture of Int-25 (150 mg, 0.729 mmol, 1 equiv), R-4 (374.87 mg, 0.875 mmol, 1.2 equiv), Pd(PPh.a)4 (168.57 mg, 0.146 mmol, 0.2 equiv) and Na2COs (154.61 mg, 1.458 mmol, 2 equiv) in dioxane (2 mL) and H2O (0.4 mL) was stirred for 2h at 80°C under N2 atmosphere. The reaction mixture was allowed to cool down to RT, then was extracted with EA (3 x 10 ml). The combined organic layers were washed with saturated brine (2x30 ml), dried over anhydrous ISfeSCL, and fdtered. The filtrate was concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (eluted with DCM / MeOH (1 :1)) to afford Int-26 (300 mg, 87.23%) as a yellow solid. LCMS (ESI): m / z = 472 [M+H]+.
[0261] Step 4: A solution of Int-26 (290 mg, 0.615 mmol, 1 equiv) and CS2CO3 (2003.76 mg, 6.150 mmol, 10 equiv) in MeOH (5 mL) was stirred for 4h at 25°C. The reaction mixture was then concentrated under reduced pressure, and the crude residue was purified by Prep-TLC (DCM / MeOH=15 / l) to afford the crude product, which was purified by prep-HPLC (Method 7) to afford Compound 1-91 (19.0 mg, 9.51%) as white solid . LCMS (ESI): m / z = 318 [M+H]+. ' H NMR (400 MHz, DMSO-d6) 5 12.20 (s, 1H), 8.06 - 8.02 (m, 2H), 7.99 - 7.94 (m, 1H), 7.40 (t, J = 2.7 Hz, 1H), 6.94 (dd, J = 2.7, 1.7 Hz, 1H), 3.64 (s, 3H), 3.46 (s, 3H), 2.63 (s, 3H).Example 12 - Method K: Synthesis of Compound 1-98
[0262] Step 1: A solution of R-l (500 mg, 2.422 mmol, 1 equiv) and (methylsulfanyl)sodium (203.65 mg, 2.906 mmol, 1.2 equiv) in DMSO (5 mL) was stirred for 3h at RT. The reaction mixture was then extracted with EA (3 x 20 ml), and the combined organic layers were washed with saturated brine (3x50 ml), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (eluted with PE / EA (5: 1)) to afford Int-24 (300 mg, 56.80%) as a white solid. LCMS (ESI): m / z = 174 [M+H]+.
[0263] Step 2: A mixture of Int-24 (150 mg, 0.688 mmol, 1 equiv), (acetyloxy )(phenyl)- lambda3-iodanyl acetate (664.55 mg, 2.064 mmol, 3 equiv) and ammonium carbamate (134.23 mg, 1.720 mmol, 2.5 equiv) in MeOH (2 mL) was stirred for 2h at room temperature under N2 atmosphere. The reaction mixture was then concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (eluted with DCM / MeOH (15: 1)) to afford Int-27 (130 mg, 92.36%) as a yellow oil. LCMS (ESI): m / z = 204 [M+H]+.
[0264] Step 3: A mixture of Int-27 (120 mg, 0.586 mmol, 1 equiv), R-2 (284.52 mg, 0.703 mmol, 1.2 equiv), Pd(PPh.3)4 (135.51 mg, 0.117 mmol, 0.2 equiv) and Na2COs (124.28 mg, 1.172 mmol, 2 equiv) in dioxane (2 mL) and H2O (0.4 mL) was stirred for 1.5 h at 80°C under N2atmosphere. The reaction mixture was then allowed to cool down to RT, was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluted with DCM / MeOH (15: 1)) to afford Int-28 (200 mg, 76.37%) as a yellow oil. LCMS (ESI): m / z = 447 [M+H]+.
[0265] Step 4: A solution of Int-28 (190 mg, 0.425 mmol, 1 equiv) and TBAF (1112.26 mg, 4.250 mmol, 10 equiv) in THF (5 mL) was stirred for 4h at 25°C, whereupon the reaction mixture was concentrated under reduced pressure. The crude residue was purified by Prep-TLC (DCM / MeOH=15 / l) to afford the crude product, which was purified by prep-HPLC (Method 8) to afford Compound 1-98 (6.2 mg, 4.57%) as white solid. LCMS (ESI): m / z = 317.05 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 5 12.18(s,lH), 7.99 (s, 1H), 7.96 - 7.85 (m, 2H), 7.39 (t, J = 2.8 Hz, 1H), 6.93 (t, J = 2.3 Hz, 1H), 4.58 (s, 1H), 3.63 (s, 3H), 3.36 (d, J = 1.1 Hz, 3H), 2.65 (s, 3H).Example 13 - Method L: Synthesis of Compound 1-99
[0266] Step 1 : A mixture of R-7 (200 mg, 1.145 mmol, 1 equiv), R-2 (555.70 mg, 1.374 mmol, 1.2 equiv), Na2C0.3 (242.74 mg, 2.290 mmol, 2 equiv) and Pd(PPhs)4 (264.66 mg, 0.229 mmol, 0.2 equiv) in dioxane (5 mL) and H2O (1 mL) was stirred for 2 h at 80°C under N2 atmosphere. The mixture was then allowed to cool down to RT, then was extracted with EA (3 x 20 ml). The combined organic layers were washed with saturated brine (3x50 ml), dried overanhydrous Na2SC>4, and filtered. The filtrate was concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (eluted with DCM / MeOH (15:1)) to afford Int-29 (400 mg, 83.84%) as a yellow solid. LCMS (ESI): m / z = 417 [M+H]+.
[0267] Step 2: A mixture of Int-29 (390 mg, 0.936 mmol, 1 equiv), (acetyloxy )(phenyl)- lambda3-iodanyl acetate (904.55 mg, 2.808 mmol, 3 equiv) and ammonium carbamate (182.71 mg, 2.340 mmol, 2.5 equiv) in MeOH (5 mb) was stirred for 2 h at RT under N2 atmosphere. The reaction mixture was then allowed to cool down to RT, and was extracted with EA (3 x 20 ml). The combined organic layers were washed with saturated brine (3x50 ml), dried over anhydrous ISfeSCU, and filtered. The filtrate was concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (eluted with DCM / MeOH (15:1)) to afford Int-30 (390 mg, 93.07%) as a yellow solid. LCMS (ESI): m / z = 448 [M+H]+.
[0268] Step 3: A stirred solution of Int-30 (380 mg, 0.849 mmol, 1 equiv) in DCM (3 mL) was treated with TFA (3 mL, 40.389 mmol, 47.58 equiv) dropwise at RT. The resulting reaction mixture was stirred for 2 h at RT, then was concentrated under reduced pressure to afford Int-31, which was then treated with NHs(g) in MeOH (3 mL, 7M). The resulting reaction mixture was stirred for 2 h at RT, then was concentrated under reduced pressure. The resulting crude residue was purified by prep-HPLC (Method 9) to provide Compound 1-99 (52.0 mg, 19.30%) as yellow solid. LCMS (ESI): m / z = 318.15 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 6 12.21 (s, 1H), 8.90 (s, 1H), 7.75 (s, 1H), 7.37 (s, 1H), 6.51 (s, 1H), 4.48 (s, 1H), 3.63 (s, 3H), 3.31 (s, 3H), 2.47 (s, 3H).Example 14 - Compound Characterization
[0269] Exemplary compounds were characterized by LC-MS. The data is provided in Table 2, below.Table 2. Compound LC-MS Characterization Data
[0270] Exemplary compounds were characterized using *HNMR. Resulting data provided in Table 3.Table 3. Compound1H Characterization DataExample 15 - ABCB11 E297G Assay
[0271] To assess activity against ABCB11 E297G, the compounds were screened in an assay measuring protein expression, using cells transfected with cDNA encoding HiBit-tagged ABCB11 E297G.
[0272] Here we describe an assay for measuring the expression of the E297G variant of human ABCB11 (henceforth referred to as ABCB11 E297G) and the use of this assay tomeasure the efficacy of compounds to increase the expression of ABCB1 1 E297G. The assay was designed to characterize the efficacy and potency of compounds to increase the expression of ABCB11 E297G by calculating an Emaxand EC50value. HEK-293 cells stably expressing E297G (HEK-293 / E297G cells) were used for this assay and were maintained at 37°C (5% CO2, humidified) in Eagle's Minimum Essential Medium supplemented with 10% fetal bovine serum and 1% Glutamine. For the assay, the HEK-293 / E297G cells were seeded in black / transparent- bottom 384-well plates at 20,000 cells / well in 22.5 pl Opti-MEM (Thermofisher, product # 11058021) media supplemented with 2.7% of fetal bovine serum (Gibco, product # 16000044) and allowed to settle for 4 hours at 37°C (5% CO2, humidified). Compound serial dilutions are prepared in Opti-MEM as four times (4x) the final concentration and using a dilution factor of 2.15. After the four h incubation period, 7.5 pL of the 4x dilutions are transferred to the assay plate.
[0273] Dose response curves include eight doses with the top final concentration at 25 μM in 0.75% DMSO. Liquid handling is performed in a robotic device equipped with a 384-tip head (Analytik Jena - CyBio Vario). After addition of compound treatment, cells are incubated for 24 hours at 37°C (5% CO2, humidified). After the 24-hour treatment, plates are allowed to equilibrate for 30 minutes at room temperature. Using the Analytik Jena - CyBio Vario instrument, the volume of each well is reduced to 15 pl and 15 pl of HiBit lytic assay reagent (Promega, product # N3040), which is prepared according to manufacturer’s instructions, is added back to each well. The plates are incubated at room temperature for additional 30 minutes and luminescent signal is acquired using a Hamamatsu FDSS 7000 EX plate-reader (20 reads, exposure time 0.2 seconds, gain 200).
[0274] Results are presented below in Table 4 for ABCB11 E297G. Compounds having an activity designated as "A" provided an ECso<l μM, Emax>1.2; compounds having an activity designated as "B" provided an EC 50 1-10 μM, Emax >1 2; compounds having an activity designated as "C" provided an EC5010-25 μM, Emax>1.2; compounds having an activity designated as "D" provided an EC50>25 μM, Emax<1.2.Table 4.Example 16 - ABCB11 WT Assay
[0275] To assess activity against ABCB 11 WT, the compounds were screened in an assay measuring protein expression, using cells transfected with cDNA encoding HiBit-tagged ABCB 11 WT. The assay was performed as described in Example 12.
[0276] Results are presented below in Table 5 for ABCB 11 WT. Compounds having an activity designated as "A" provided an ECso<l μM, Emax>1.2; compounds having an activity designated as "B" provided an ECso 1-10 μM, Emax >1 2; compounds having an activity designated as "C" provided an EC5010-25 μM, Emax>1.2; compounds having an activity designated as "D" provided an EC50>25 μM, Emax<1.2.Table 5.Example 17 - ABCC6 WT Assay
[0277] To assess activity against ABCC6, the compounds were screened in an assay measuring protein expression, using cells transfected with cDNA encoding HiBit-tagged ABCC6 wild-type.
[0278] Here we describe an assay for measuring the expression of the wild type of human ABCC6 (henceforth referred to as ABCC6 WT) and the use of this assay to measure the efficacy of compounds to increase the expression of ABCC6 WT. The assay was designed to characterize the efficacy and potency of compounds to increase the expression of ABCC6 WT by calculatingan Emaxand EC50value. HEK-293 cells transiently expressing ABCC6 WT (HEK-293 / ABCC6 WT) were used for this assay and were cultured at 37°C (5% CO2, humidified) in Dulbecco's Modified Eagle Medium (DMEM, Gibco product #11965-092) supplemented with 10% fetal bovine serum. For the assay, HEK-293 cells were transfected with 4.5pg carrier DNA and 0.24 pg / 10 cm plate of cDNA encoding HiBit-tagged ABCC6 wild-type using Lipofectamine 3000 (Thermo Fisher, product # L3000-015). Twenty -four hours after transfection, the HEK- 293 / ABCC6 WT cells were seeded in white / opaque 384-well plates (Corning, product #3570) at 10,000 cells / well in 20 pl growth medium and allowed to settle for 4 hours at 37°C (5% CO2, humidified). Compound serial dilutions are prepared in growth medium as ten times (lOx) the final concentration and using a dilution factor of 2. After the four-hour incubation period, 2.2 pL of the lOx dilutions are transferred to the assay plate.
[0279] Dose response curves include eleven doses with the top final concentration at 30 μM in 0.3% DMSO. Liquid handling is performed with ECHO 550 Acoustic Liquid Handler (Labcyte). After addition of compound treatment, cells are incubated for 24 hours at 37°C (5% CO2, humidified). After the 24-hour treatment, plates are allowed to equilibrate to room temperature for 10 minutes. Using Dragonfly Automated Liquid Handler (TTP LabTech), 20 pl of HiBit lytic assay reagent (Promega, product # N3050), which is prepared according to manufacturer’s instructions, is added to each well. The plates are rotated at room temperature for 2 minutes and incubated for 1 hour at 25 °C before luminescent signal is acquired using an EnVision Multimode Plate Reader (PerkinElmer).
[0280] Results are presented below in Table 6 for ABCC6 WT. Compounds having an activity designated as "A" provided an ECsoM μM, Emax >1 2; compounds having an activity designated as "B" provided an EC 50 1-10 μM, Emax>1.2; compounds having an activity designated as "C" provided an EC5010-25 μM, Emax >1 2; compounds having an activity designated as "D" provided an EC50>25 μM, Emax<1.2.Table 6.Example 15 - ABCB4 WT Assay
[0281] To assess activity against ABCB4, the compounds were screened in an assay measuring protein expression, using cells transfected with cDNA encoding HiBit-tagged ABCB4 wild-type.
[0282] Here we describe an assay for measuring the expression of the wild type of human ABCB4 (henceforth referred to as ABCB4 WT) and the use of this assay to measure the efficacy of compounds to increase the expression of ABCB4 WT. The assay was designed to characterize the efficacy and potency of compounds to increase the expression of ABCB4 WT by calculating an Emaxand EC50value. HEK-293 cells stably expressing ABCB4 WT (HEK-293 / ABCB4 WT) were used for this assay and were maintained at 37°C (5% CO2, humidified) in Dulbecco's Modified Eagle Medium (DMEM, Gibco product # 12100) supplemented with 10% fetal bovine serum (Biosera product # FB-1058 / 500), 1% PenStrep (HDB product # 15140-122), and 0.5 mg / mL puromycin (Gibco product # Al 1138-03). For the assay, the HEK-293 / ABCB4 WT cellswere seeded in white / opaque 384-well plates (Corning product # 3570) at 10,000 cells / well in 20 μl growth medium and allowed to settle for 4 hours at 37°C (5% CO2, humidified). Compound serial dilutions are prepared in DMSO as three hundred times (333x) the final concentration and using a dilution factor of 3 using Bravo (Agilent). After the four-hour incubation period, 60 nL of DMSO solutions are transferred to the assay plate.
[0283] Dose response curves include eleven doses with the top final concentration at 30 μM in 0.3% DMSO. Liquid handling is performed with ECHO 550 Acoustic Liquid Handler (Labcyte). After addition of compound treatment, cells are incubated for 24 hours at 37°C (5% CO2, humidified). After the 24-hour treatment, plates are allowed to equilibrate to room temperature for 10 minutes. Using Dragonfly Automated Liquid Handler (TTP LabTech), 20 μl of HiBit lytic assay reagent (Promega, product # N3040), which is prepared according to manufacturer’s instructions, is added to each well. The plates are rotated at room temperature for 2 minutes and incubated for 1 hour at 25 °C before luminescent signal is acquired using an EnVision Multimode Plate Reader (PerkinElmer).
[0284] Results are presented below in Table 7 for ABCB4 WT. Compounds having an activity designated as "A" provided an EC50<l μM, Emax>1 .2; compounds having an activity designated as "B" provided an EC501-10 μM, Emax >1.2; compounds having an activity designated as "C" provided an EC5010-25 μM, Emax>1.2; compounds having an activity designated as "D" provided an EC50>25 μM, Emax<1.2.Table 7.Example 18 - ABCA4 P1380L Assay
[0285] To assess activity against ABCA4 P1380L, the compounds were screened in an assay measuring protein expression, using cells transfected with cDNA encoding HiBit-tagged ABCA4 P1380L variant.
[0286] Here we describe an assay for measuring the expression of the P1380L variant of human ABCA4 (henceforth referred to as ABCA4 P1380L) and the use of this assay to measure the efficacy of compounds to increase the expression of ABCA4 P1380L. The assay was designed to characterize the efficacy and potency of compounds to increase the expression of ABCA4 P1380L by calculating an Emaxand EC50value. HEK-293 cells cells transiently expressing ABCD2 WT (HEK-293 / ABCD2 WT) were used for this assay and were cultured at 37°C (5% CO2, humidified) in Dulbecco's Modified Eagle Medium (DMEM, Gibco product #11965-092) supplemented with 10% fetal bovine serum. For the assay, HEK-293 cells were transfected with 0.24 μg / 10 cm plate of cDNA encoding HiBit-tagged ABCD2 wild-type using Lipofectamine 3000 (Thermo Fisher, product # L3000-015). Twenty-four hours after transfection, the HEK-293 / ABCD2 WT cells were seeded in white / opaque 384-well plates (Coming, product #3570) at 10,000 cells / well in 20 pl growth medium and allowed to settle for 4 hours at 37°C (5% CO2, humidified). Compound serial dilutions are prepared in growth medium as ten times ( 10x) the final concentration and using a dilution factor of 2. After the four-hour incubation period, 2.2 μL of the lOx dilutions are transferred to the assay plate.
[0287] Dose response curves include eleven doses with the top final concentration at 30 μM in 0.3% DMSO. Liquid handling is performed with ECHO 550 Acoustic Liquid Handler (Labcyte). After addition of compound treatment, cells are incubated for 24 hours at 37°C (5% CO2, humidified). After the 24-hour treatment, plates are allowed to equilibrate to room temperature for 10 minutes. Using Dragonfly Automated Liquid Handler (TTP LabTech), 20 pl of HiBit lytic assay reagent (Promega, product # N3040), which is prepared according to manufacturer’s instructions, is added to each well. The plates are rotated at room temperature for 2 minutes and incubated for 1 hour at 25 °C before luminescent signal is acquired using an EnVision Multimode Plate Reader (PerkinElmer).
[0288] Results are presented below in Table 8 for ABCA4 P1380L. Compounds having an activity designated as "A" provided an ECsoM μM, Emax>1.2; compounds having an activity designated as "B" provided an EC501-10 μM, Emax>L2; compounds having an activity designated as "C" provided an EC5010-25 μM, Emax >1 2; compounds having an activity designated as "D" provided an EC50>25 μM, Emax<1.2.Table 8.Example 17 - ABCD2 WT Assay
[0289] To assess activity against ABCD2, the compounds were screened in an assay measuring protein expression, using cells transfected with cDNA encoding HiBit-tagged ABCD2 wild-type.
[0290] Here we describe an assay for measuring the expression of the wild type of human ABCD2 (henceforth referred to as ABCD2 WT) and the use of this assay to measure the efficacy of compounds to increase the expression of ABCD2 WT. The assay was designed to characterize the efficacy and potency of compounds to increase the expression of ABCD2 WT by calculating an Emaxand EC50value. HEK-293 cells stably expressing ABCD2 WT (HEK-293 / ABCD2 WT) were used for this assay and were maintained at 37°C (5% CO2, humidified) in Dulbecco's Modified Eagle Medium (DMEM, Gibco product # 12100) supplemented with 10% fetal bovine serum (Biosera product # FB-1058 / 500), 1% PenStrep (1TDB product # 15140-122), and 0.5 mg / mL puromycin (Gibco product # Al 1138-03). For the assay, the HEK-293 / ABCD2 WT cells were seeded in white / opaque 384-well plates (Corning product # 3570) at 10,000 cells / well in 20 pl growth medium and allowed to settle for 4 hours at 37°C (5% CO2, humidified). Compound serial dilutions are prepared in DMSO as three hundred times (333x) the final concentration and using a dilution factor of 3 using Bravo (Agilent). After the four-hour incubation period, 60 nL of DMSO solutions are transferred to the assay plate.
[0291] Dose response curves include eleven doses with the top final concentration at 30 μM in 0.3% DMSO. Liquid handling is performed with ECHO 550 Acoustic Liquid Handler (Labcyte). After addition of compound treatment, cells are incubated for 24 hours at 37°C (5% CO2, humidified). After the 24-hour treatment, plates are allowed to equilibrate to roomtemperature for 10 minutes. Using Dragonfly Automated Liquid Handler (TTP LabTech), 20 pl of HiBit lytic assay reagent (Promega, product # N3040), which is prepared according to manufacturer’s instructions, is added to each well. The plates are rotated at room temperature for 2 minutes and incubated for 1 hour at 25 °C before luminescent signal is acquired using an EnVision Multimode Plate Reader (PerkinElmer).
[0292] Results are presented below in Table 9 for ABCD2 WT. Compounds having an activity designated as "A" provided an ECso<l μM, Emax>1 .2; compounds having an activity designated as "B" provided an EC501-10 μM, Emax>1.2; compounds having an activity designated as "C" provided an ECso 10-25 μM, Emax>1 2; compounds having an activity designated as "D" provided an EC50>25 μM, Emax<1.2.Table 9.INCORPORATION BY REFERENCE
[0293] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.EQUIVALENTS
[0294] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.References:1. Vauthier, V. et al. (2017) Targeted pharmacotherapies for defective ABC transporters. Biochem Pharmacol ' 136, 1-11. 10.1016 / j .bcp.2017.02.0202. Dean, M. et al. (2022) The human ATP -binding cassette (ABC) transporter superfamily. Hum Mutat e, 1162-1182. 10.1002 / humu.244183. Liu, X. (2019) ABC Family Transporters. Adv Exp Med Biol 1141, 13-100. 10.1007 / 978- 981-13-7647-4_24. Molday, R.S. et al. (2022) Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog Retin Eye Res 89, 101036.10.1016 / j .preteyeres.2021.1010365. Kroll, T. et al. (2021) Structure and Function of Hepatobiliary ATP Binding Cassette Transporters. Chem Rev 121, 5240-5288. 10.1021 / acs.chemrev.0c006596. Wanders, R.J. et al. (2007) The peroxisomal ABC transporter family. Pfhigers Arch 453, 719-734. 10.1007 / s00424-006-0142-x7. Shaughnessy, C. A. et al. (2021 ) Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep 11, 19810. 10.1038 / s41598-021 -99184- 18. Thomas, C. and Tampe, R. (2020) Structural and Mechanistic Principles of ABC Transporters. Anmi Rev Biochem 89, 605-636. 10.1146 / annurev-biochem-011520-1052019. Byrne, J. A. et al. (2009) Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing. Hepatology 49, 553-567. 10.1002 / hep.2268310. Gunaydin, M. and Bozkurter Cil, A T. (2018) Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. HepatMed 10, 95-104.10.2147 / HMER. SI 3720911. Bosma, P.J. et al. (2020) Gene Therapy for Progressive Familial Intrahepatic Cholestasis: Current Progress and Future Prospects. Int J Mol Sci 22. 10.3390 / ijms2201027312. Boyer, J.L. (2013) Bile formation and secretion. Compr Physiol 3, 1035-1078. 10.1002 / cphy.cl2002713. Gerloff, T. et al. (1998) The sister of P-gly coprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273, 10046-10050. 10.1074 / jbc.273.16.1004614. van der Woerd, W.L. et al. (2017) Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol ' 23, 763-775. 10.3748 / wjg.v23.i5.76315. Wang, L. et al. (2020) Cryo-EM structure of human bile salts exporter ABCB11. Cell Res 30, 623-625. 10.1038 / s41422-020-0302-016. Boyer, J.L. and Soroka, C.J. (2021) Bile formation and secretion: An update. J Hepatol 75, 190-201. 10.1016 / j .jhep.2021.02.01117. ALDury, S. and Marschall, H.U. (2018) Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. Front Pharmacol 9, 931. 10.3389 / fphar.2018.0093118. van Wessel, D.B.E. etal. (2020) Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol 73, 84-93. 10.1016 / j.jhep.2020.02.00719. Stattermayer, A.F. et al. (2020) Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol TS, 651-663. 10.1016 / j.jhep.2020.04.03620. Nayagam, J.S. et al. (2022) Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1. Hepatol Commun. 10.1002 / hep4.205121. Stapelbroek, J.M. et al. (2010) Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 52, 258-271. 10.1016 / j.jhep.2009.11.01222. Thompson, R.J. et al. (2022) Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 7, 830-842. 10.1016 / S2468-1253(22)00093-023. Le Saux, O. et al. (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 25, 223-227. 10.1038 / 7610224. Iwanaga, A. and Murota, H. (2022) Author reply to comment on "Clinical practice guidelines for pseudoxanthoma elasticum (2017)": The importance of mutation analysis. J Dermatol^, e250. 10.1111 / 1346-8138.1637925. Borst, P. et al. (2019) PXE, a Mysterious Inborn Error Clarified. Trends Biochem Sci 44, 125-140. 10.1016 / j.tibs.2018.10.00526. Nitschke, Y. and Rutsch, F. (2012) Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin. Front Genet 3, 302.10.3389 / fgene.2012.0030227. Ferreira, C.R. et al. (2021) Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies. J Bone Miner Res 36, 2193-2202.10.1002 / jbmr.441828. Bartstra, J.W. et al. (2021) Genotype-phenotype correlation in pseudoxanthoma elasticum. Atherosclerosis 324, 18-26. 10.1016 / j. atherosclerosis.2021.03.01229. Matsuzaki, Y. et al. (2005) Tissue-specific expression of the ABCC6 gene. J Invest Dermatol 125, 900-905. 10.111 l / j.0022-202X.2005.23897.x30. Scheffer, G.L. et al. (2002) MRP6 (ABCC6) detection in normal human tissues and tumors. Lab Invest 82, 515-518. 10.1038 / labinvest.378044431. Jansen, R.S. etal. (2014) ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vase Biol 34, 1985-1989. 10.1161 / ATVBAHA.114.30401732. Jansen, R.S. etal. (2013) ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Set USA 110, 20206-20211. 10.1073 / pnas. l31958211033. Iwanaga, A. et al. (2022) Clinical practice guidelines for pseudoxanthoma elasticum (2017): Clinical Practice Guidelines for Pseudoxanthoma Elasticum Drafting Committee. J Dermatol 49, e91-e98. 10.1111 / 1346-8138.1630134. Fong, V. and Patel, S.B. (2021) Recent advances in ABCG5 and ABCG8 variants. Curr Opin Lipidol 32, 117-122. 10. 1097 / MGL.000000000000073435. Hooper, A.J. et al. (2017) Clinical utility gene card for: Sitosterolaemia. Eur J Hum Genet 25. 10.1038 / ejhg.2016.18736. Bhattacharyya, A.K. and Connor, W.E. (1974) Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 53, 1033-1043.10.1172 / JCI10764037. Patel, S.B. et al. (1998) Sitosterolemia: exclusion of genes involved in reduced cholesterol biosynthesis. J Lipid Res 39, 1055-106138. Williams, K. et al. (2021) Sitosterolemia: Twenty Years of Discovery of the Function of ABCG5ABCG8. IntJMol Sci 22. 10.3390 / ijms2205264139. Graf, G.A. et al. (2002) Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest 110, 659-669.10.1172 / JCI 1600040. Jakulj, L. et al. (2016) Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion. Cell Metab 24, 783-794. 10.1016Zj.cmet.2016.10.00141. Zein, A.A. et al. (2019) ABCG5 / G8: a structural view to pathophysiology of the hepatobiliary cholesterol secretion. Biochem Soc Trans 47, 1259-1268. 10.1042 / BST2019013042. Chen, Z.C. et al. (2008) Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance. J Hum Genet 53, 757-763. 10.1007 / sl0038- 008-0310-243. Rust, S. et al. (1999) Tangier disease is caused by mutations in the gene encoding ATP- binding cassette transporter 1. Nat Genet 22, 352-355. 10.1038 / 1192144. Schaefer, E.J. et al. (2016) Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis 59, 97-106. 10.1016 / j.pcad.2016.08.00645. Maranghi, M. et al. (2019) A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family. Biochem Biophys Res Commun 508, 487-493. 10.1016 / j.bbrc.2018.11.06446. Koseki, M. et al. (2021) Current Diagnosis and Management of Tangier Disease. J Atheroscler Thromb 28, 802-810. 10.555 l / jat.RV1705347. Langmann, T. et al. (1999) Molecular cloning of the human ATP-binding cassette transporter 1 (hABCl): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 257 , 29-33. 10.1006 / bbrc.1999.040648. Hoekstra, M. et al. (2003) Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem ZIZ, 25448-25453. 10.1074 / jbc.M30118920049. Wang, X. et al. (2007) Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 117, 2216-2224.10.1172 / JCI3205750. Oram, J.F. and Lawn, R.M. (2001) ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42, 1173-117951. Oram, J.F. et al. (2000) ABCA1 is the cAMP -inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275, 34508-34511 .10.1074 / jbc.M00673820052. Brunham, L.R. et al. (2007) Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13, 340-347. 10.1038 / nml54653. Wang, N. et al. (2000) Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 275, 33053- 33058. 10.1074 / jbc.M00543820054. Jacobo-Albavera, L. et al. (2021) The Role of the ATP-Binding Cassette Al (ABCA1) in Human Disease. Int J Mol Sci 22. 10.3390 / ijms2204159355. Al-Khuzaei, S. et al. (2021) An Overview of the Genetics of ABCA4 Retinopathies, an Evolving Story. Genes (Basel) 12. 10.3390 / genesl208124156. Tsang, S. and Sharma, T. (2018) Stargardt disease. In A tlas of Inherited Retinal Diseases (Tsang, S. and Sharma, T., eds), pp. 140-151, Springer International Publishing AG57. Tanna, P. et al. (2017) Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol 101, 25-30. 10.1136 / bjophthalmol-2016- 30882358. Kawaguchi, K. and Morita, M. (2016) ABC Transporter Subfamily D: Distinct Differences in Behavior between ABCD1-3 and ABCD4 in Subcellular Localization, Function, and Human Disease. Biomed Res Int 2016, 6786245. 10.1155 / 2016 / 678624559. Turk, B.R. et al. (2020) X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci 80, 52-72.10.1002 / jdn.1000360. Barthel, A. et al. (2019) An Update on Addison's Disease. Exp Clin Endocrinol Diabetes 127, 165-175. 10.1055 / a-0804-271561. Kawaguchi, K. et al. (2016) Translocation of the ABC transporter ABCD4 from the endoplasmic reticulum to lysosomes requires the escort protein LMBD1. Sci Rep 6, 30183. 10.1038 / srep3018362. Weinhofer. I. et al. (2018) Impaired plasticity of macrophages in X-linked adrenoleukodystrophy. Brain 141, 2329-2342. 10.1093 / brain / awyl2763. Beers, M.F. and Mulugeta, S. (2017) The biology of the ABCA3 lipid transporter in lung health and disease. Cell Tissue Res 367, 481-493. 10.1007 / s00441-016-2554-z64. Flamein, F. et al. (2012) Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet 21, 765-775. 10.1093 / hmg / ddr50865. Hammel, M. et al. (2007) Targeted inactivation of the murine Abca3 gene leads to respiratory failure in newborns with defective lamellar bodies. Biochem Biophys Res Commun 359, 947-951. 10.1016 / j.bbrc.2007.05.21966. Wambach, J. A. et al. (2022) First Steps toward Personalized Therapies for ABCA3 Deficiency. Am J Respir Cell Mol Biol 66, 349-350. 10.1165 / rcmb.2021-0405ED67. Sanders, M. et al. (2021) Genomic, transcriptomic, and protein landscape profile of CFTR and cystic fibrosis. Hum Genet 140, 423-439. 10.1007 / s00439-020-02211-w68. Amaral, M.D. (2015) Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. JInternMed 277, 155-166. 10.1111 / joim.1231469. Breijyeh, Z. and Karaman, R. (2020) Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules 25. 10.3390 / molecules2524578970. Anstey, KJ. et al. (2017) Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta- Analysis. J Alzheimers Dis 56, 215-228. 10.3233 / J AD-16082671. Torrandell-Haro, G. et al. (2020) Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 6, el2108. 10.1002 / trc2.1210872. Bossaerts, L. et al. (2022) The role of ATP -binding cassette subfamily A in the etiology of Alzheimer's disease. Mol Neurodegener 17, 31. 10.1186 / sl3024-022-00536-w73. Koi damova, R.P. et al. (2005) The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 280, 4079- 4088. 10.1074 / jbc.M41142020074. Koldamova, R. et al. (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280, 43224-43235.10.1074 / jbc.M50451320075. Zhu, X. et al. (2010) Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res 51, 3196-3206.10.1194 / jlr.M00648676. Sviridov, D. et al. (2020) Lipid rafts as a therapeutic target. J Lipid Res 61, 687-695. 10.1194 / jlr.TR12000065877. Ehehalt, R. et al. (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123. 10.1083 / jcb.20020711378. Choy, R.W. et al. (2012) Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid beta (Abeta) production in the trans-Golgi network. Proc Natl Acad Sci USA 109, E2077-2082. 10.1073 / pnas.l20863510979. Marquer, C. et al. (2011) Local cholesterol increase triggers amyloid precursor protein- Bacel clustering in lipid rafts and rapid endocytosis. FASEB J 25, 1295-1305. 10.1096 / fj .10- 16863380. Wahrle, S.E. et al. (2005) Deletion of Abcal increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Cheni 280, 43236-43242.10.1074 / jbc.M50878020081 . Lefterov. I. et al. (2009) Memory deficits in APP23 / AbcaH7- mice correlate with the level of Abeta oligomers. ASN Neuro 1. 10.1042 / AN2009001582. Jiang, Q. et al. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681-693. 10.1016 / j. neuron.2008.04.01083. Leissring, M. A. et al. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087- 1093. 10.1016 / s0896-6273(03)00787-684. Husain, M.A. et al. (2021) APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci 15, 630502. 10.3389 / fnins.2021 .63050285. Wahrle, S.E. et al. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118, 671-682. 10.1172 / JCI3362286. Boehm-Cagan, A. et al. (2016) ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. J Alzheimers Dis 54, 1219-1233. 10.3233 / JAD-16046787. Noveir, S.D. et al. (2022) Effect of the ABCA1 agonist CS-6253 on amyloid-beta and lipoprotein metabolism in cynomolgus monkeys. Alzheimers Res Ther 14, 87. 10.1186 / s 13195- 022-01028-188. Reitz, C. et al. (2013) Variants in the ATP -binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. JAMA 309, 1483-1492. 10.1001 / jama.2013.297389. Cukier, H.N. et al. (2016) ABCA7 frameshift deletion associated with Alzheimer disease in African Americans. Neurol Genet 2, e79. 10.1212 / NXG.000000000000007990. Bellenguez, C. et al. (2017) Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging 59, 220 e221- 220 e229. 10.1016 / j.neurobiolaging.2017.07.00191. De Roeck, A. et al. (2017) Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathol 134, 475-487. 10.1007 / s00401-017-1714-x92. Apostolova, L.G. et al. (2018) Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA Neurol 75, 328-341. 10.1001 / jamaneurol.2017.419893. Stage, E. et al. (2016) The effect of the top 20 Alzheimer disease risk genes on graymatter density and FDG PET brain metabolism. Alzheimers Dement (Amst) 5, 53-66.10.1016 / j.dadm.2016.12.00394. Lyssenko, N.N. and Pratico, D. (2021) ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease. Alzheimers Dement 17, 164-174. 10.1002 / alz.1222095. Lamartiniere, Y. et al. (2018) ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and Decreases Amyloid-beta Peptide Efflux in an in vitro Model of the Blood- Brain Barrier. J Alzheimers Dis 64, 1195-1211. 10.3233 / J AD-17088396. Tanaka, N. et al. (2010) Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP -binding cassette transporter A7. J Lipid Res 51, 2591-2599. 10.1194 / jlr.M00604997. Jehle, A.W. et al. (2006) ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol 174, 547-556.10.1083 / jcb.20060103098. Aikawa, T. et al. (2019) ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain. Proc NatlAcadSci USA 116, 23790-23796. 10.1073 / pnas.190852911699. Satoh, K. et al. (2015) ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J Biol Chem 290, 24152-24165. 10.1074 / jbc.Ml 15.655076100. Sakae, N. et al. (2016) ABCA7 Deficiency Accelerates Amyloid-beta Generation and Alzheimer's Neuronal Pathology. J Neurosci 36, 3848-3859. 10.1523 / JNEUROSCI.3757- 15.2016101. Kim, W.S. et al. (2013) Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci 33, 4387-4394.10.1523 / JNEUROSCI.4165-12.2013
Claims
We Claim:
1. A compound represented by Formula I: wherein:R1is -L1-SO2-R6, -SO2N(R9)-R7’, or -S(NH)(O)-R6;R2represents independently for each occurrence hydrogen, hydroxyl, C1-3alkyl, halo, C1-4alkoxyl, C1.3 haloalkyl, C1-3hydroxyalkyl, or optionally substituted cyclopropyl;R3and R4are independently hydrogen or C1-3alkyl;R5represents independently for each occurrence halo, cyano, C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, -CON(R10)2, or C1-6haloalkoxyl;R6is C1-4alkyl, C3-5cycloalkyl, phenyl, -(C0-2 alkylene)-(3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl, heterocycle, and heteroaryl are substituted with m instances of R8;R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, or -(C0-2 alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8;R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl;R9is hydrogen or C1-3alkyl;R10represents independently for each occurrence hydrogen, C1-4alkyl, or cyclopropyl;L1is -N(R9)- or a bond;A* is an 8-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 memberedbicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;B1is phenylene or a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen; m is 0, 1, or 2; n is 0, 1, 2, or 3; o is 1, 2, or 3; and p is 0, 1 or 2.
2. The compound of claim 1, wherein the compound is a compound of Formula I.
3. The compound of claim 1 or, wherein1 A* is an 8-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
4. The compound of claim 1 or, wherein A* is a 9-10 membered partially unsaturated bicyclic oxo-heterocyclic ring containing two heteroatoms, wherein the heteroatoms are nitrogen atoms.
5. A compound represented by Formula 1-1 :or a pharmaceutically acceptable salt thereof; wherein:R1is -L1-SO2-R6, -SO2N(R9)-R7’, or -S(NH)(O)-R6;R2represents independently for each occurrence hydrogen, hydroxyl, C1-3alkyl, halo, C1-4alkoxyl, C1.3 haloalkyl, C1-3hydroxyalkyl, or optionally substituted cyclopropyl;R3and R4are independently hydrogen or C1-3alkyl;R5represents independently for each occurrence halo, cyano, C1-6alkyl, C1-6haloalkyl, hydroxyl, C1-6alkoxyl, or C1-6haloalkoxyl;R6is C1-4alkyl, C3-5cycloalkyl, phenyl, -(C0-2 alkylene)-(3-7 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or -(C0-2alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl, heterocycle, and heteroaryl are substituted with m instances of R8;R7is hydrogen, C1-4alkyl, C3-5cycloalkyl, phenyl, or -(C0-2alkylene)-(5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), wherein the cycloalkyl and heteroaryl are substituted with m instances of R8;R8represents independently for each occurrence C1-4alkyl, halo, C1-3haloalkyl, hydroxyl, C1-4alkoxy, cyano, or cyclopropyl;R9is hydrogen or C1-3alkyl;L1is -N(R9)- or a bond;A1is a 5-6 membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur;B1is phenylene or a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen; m is 0, 1, or 2; n is 0, 1, 2, or 3; and o is 1, 2, or 3.
6. The compound of claim 5, wherein the compound is a compound of Formula I-1.
7. The compound of claim 5, wherein the compound is a compound of Formula I-A, or a pharmaceutically acceptable salt thereof:
8. The compound of claim 5, wherein the compound is a compound of Formula I-B, LC, LD, I- E, or LF, or a pharmaceutically acceptable salt thereof:
9. The compound of claim 5, wherein the compound is a compound of Formula LG, or a pharmaceutically acceptable salt thereof:
10. The compound of any one of claims 5-9, wherein A1is a 5-membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
11. The compound of any one of claims 5-9, wherein A1is a 6-membered partially unsaturated or aromatic ring containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
12. The compound of claim 5, wherein the compound is a compound of Formula I-H, I-I, I- J, I- K, I-L, I-M, or I-N, or a pharmaceutically acceptable salt thereof:
13. The compound of any one of claims 1-7 or 12, wherein B1is a 6-membered monocyclic heteroaromatic ring containing 1 or 2 heteroatoms selected from nitrogen.
14. The compound of any one of claims 1-7 or 12, wherein B1is pyridinylene, pyrimidylene, pyridazinylene, pyrazinylene, or phenylene.
15. The compound of any one of claims 1-7 or 12, wherein B1is pyridinylene.
16. The compound of any one of claims 1-7 or 12, wherein B1is phenylene.
17. The compound of any one of claims 1-16, wherein R3is hydrogen.
18. The compound of claim 5, wherein the compound is a compound of Formula I-O, I-P, I-Q, or I-R, or a pharmaceutically acceptable salt thereof19. The compound of any one of claims 1-18, wherein n is 1 or 2.
20. The compound of any one of claims 1-19, wherein R1is -JJ-SCh-R6.21 . The compound of any one of claims 1-20, wherein L1is -N(R9)-.
22. The compound of any one of claims 1-20, wherein L1is a bond.
23. The compound of any one of claims 1-19, wherein R1is -S(NH)(O)-R6.
24. The compound of any one of claims 1-23, wherein R6is Ci-4 alkyl.
25. The compound of any one of claims 1-23, wherein R6is / -butyl.
26. The compound of any one of claims 1-23, wherein R6is C3-5cycloalkyl.
27. The compound of any one of claims 1-23, wherein R6is cyclopropyl.
28. The compound of any one of claims 1-19, wherein R1is -SO2N(R9)-R7.
29. The compound of any one of claims 1-19 or 28, wherein R7is C1-4alkyl.
30. The compound of any one of claims 1-19 or 28, wherein R7is / -butyl.
31. The compound of any one of claims 1-19 or 28, wherein R7is C3-5cycloalkyl.
32. The compound of any one of claims 1-19 or 28, wherein R7is cyclopropyl.
33. The compound of any one of claims 1-32, wherein R4is methyl.
34. The compound of any one of claims 1-33, wherein R2is C1-3alkyl, halo, C1-3haloalkyl, or cyclopropyl.
35. The compound of any one of claims 1-33, wherein R2is methyl or optionally substituted cyclopropyl.
36. The compound of any one of claims 1-35 wherein R2is methyl or cyclopropyl.
37. The compound of any one of claims 1-35 wherein R2is methyl or 1 -methylcyclopropyl.
38. The compound of any one of claims 1-37, wherein R8is C1-4alkyl or C1-3haloalkyl.
39. The compound of any one of claims 1-37, wherein R8is methyl.
40. The compound of any one of claims 1-39, wherein R9is hydrogen.
41. The compound of any one of claims 1-40, wherein n is 0.
42. A compound of Table 1 or a pharmaceutically acceptable salt thereof.
43. A pharmaceutical composition comprising a compound of any one of claims 1 -42 and a pharmaceutically acceptable carrier.
44. A method of treating a disorder associated with ABC transporter dysfunction, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-42 to treat the disorder.
45. The method of claim 44, wherein the disorder associated with ABC transporter dysfunction is characterized by dysfunction in a transporter selected from one or more of ABCA1, ABCA2, ABCA3, ABCA4, ABCA5, ABCA7, ABCA12, ABCB2, ABCB3, ABCB4, ABCB6, ABCB7, ABCB10, ABCB11, ABCC1, ABCC2, ABCC4, ABCC5, ABCC6 ABCC7, ABCC8, ABCC9, ABCC12, ABCD1, ABCD2, ABCD3, ABCD4 , ABCG5, ABCG8, ABCG1, and ABCG4.
46. A method of treating a disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-42 to treat the disorder, wherein the disorder is selected from Tangier disease, Surfactant metabolism dysfunction pulmonary 3, autosomal recessive Ichthyosis congenital 4A (ARCI), Bare lymphocyte syndrome type I, Bare lymphocyte syndrome type I due to TAP2 deficiency, Dyschromatosis universalis hereditaria 3, X-linked sideroblastic anemia with ataxia, Dubin- Johnson Syndrome, Cystic fibrosis (CF), Familial Hyperinsulinemic Hypoglycemia 1, Intellectual disability Myopathy Syndrome, Congenital bile acid synthesis defect 5, Methylmalonic aciduria and homocystinuria cblJ type, Sitostrolemia, Stargardt disease, PFIC3, PFIC2, Pseudoxanthoma Elasticum, X-linked adrenoleukodystrophy (ALD), Cholestasis, Hyperbilirubinemia, Intrahepatic cholestasis of pregnancy, Biliary atresia, Alagille syndrome, primary biliary cholangitis, primary sclerosing cholangitis, NAFLD / NASH, Alzheimer's disease, Huntington's disease, Multiple sclerosis, Parkinson’s disease, Hirschsprung disease, Zellweger syndrome, Type 2 diabetes, Obesity, Type 1 diabetes, Atherosclerosis, Dyslipidemia, Generalized arterial calcification of infancy, Calciphylaxis, Autosomal recessive cone-rod dystrophy, Gout, PFIC1, Myo5B deficiency cholestasis, PFIC4, and Low phospholipid associated cholelithiasis.
47. The method of claim 46, wherein the disorder is Cystic fibrosis.
48. A method of increasing the expression of a protein selected from ABCB11 , ABCB1 1 E297G, ABCC6, ABCB4, ABCA4 P1380L, and ABCD2 in a subject, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-42 to thereby increase expression of said protein.
49. The method of any of claims 44-48, wherein the subject is a human.
Citation Information
Patent Citations
1-(2H)-isoquinolone derivative
EP1854792A1
Bromodomain inhibitors
WO2013097601A1
3-ARYL-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2013132253A1
Aldo-KETO reductase subfamily 1c3 (AKR1c3) inhibitors
WO2013142390A1
Bromodomain inhibitors
WO2015058160A1
Cited By
Bipyridinyl sulfonamides and related compounds and their use in treating medical conditions
WO2026202016A1
